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1. Introduction 
 
1.1. Hepadnaviridae  
 
Hepatitis B virus (HBV) is a member of the family Hepadnaviridae and belongs to the 
Orthohepadnavirus genus. The genome of HBV is circular and partially double-stranded with 
a size of only about 3.2 kb. The family of Hepadnaviridae including the mammalian 
(Orthohepadnavirus) and avian (Avihepadnavirus) species have a common structure and lead 
to persistent virus infection. Table 1 sums up members of Hepadnaviridae (Blumberg et al., 
1967; Summers et al., 1978; Marion et al., 1980; Mason et al., 1980; Sprengel et al., 1988; 
Testut et al., 1996; Lanford et al., 1998; Chang et al., 1999; Warren et al., 1999) and their 
natural hosts (Tab. 1).  
 
Table 1: Hepadnaviridae and their natural hosts 
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1.2. The viral morphology  
 
Hepatitis B virus virions, also called Dane particles (Blumberg et al., 1967; Dane et al., 1970; 
Blumberg, 1977), have a diameter of approx. 42 nm (Fig. 1). The envelope of the virus 
consists of three proteins in a glycosylated and non-glycosylated form: The large (L), the 
middle (M) and the small (S) protein. The S protein (226 amino acids) is encoded by s gene. 
PreS2 and s genes encode the M protein (281 amino acids), while preS1, preS2 and s encode 
L protein (389 or 400 amino acids, depending on the subtype). The HBV genome is 
encapsulated by the nucleocapsid (core) protein (HBcAg) and bears viral DNA. The HBV 
core protein consists of 183 or 185 amino acids depending on the genotype and is highly 
conserved among all HBV genotypes (Chain et al., 2005). The fundamental building unit of 
HBV is formed by dimerization of two core proteins, oligomerization of the dimers and 
formation of two types of capsids: Capsids consisting of 90 dimers associated in a icosahedral 
symmetry (T = 3) of about 30 nm in diameter and capsids consisting of 120 dimers associated 
in an icosahedral symmetry (T = 4) of about 34 nm in diameter (Zheng et al., 1992; Wynne et 
al., 1999). Virus particles are present in very large quantities in peripheral blood of infected 
patients (up to 10
11 
particles/ml). Further, empty spherical or filamentous particles, approx. 22 
nm in diameters, are present (Fig. 1). The spherical particles are organized as an octahedral 
sphere containing 48 S-dimer subunits and the filamentous particles consist of the same 
diameter but differ in the length (Gilbert et al., 2005).
 
 
 
Figure 1: The composition of infectious and non-infectious particles of Hepatitis B virus.  
On the left: infectious Dane particle with PreS1, PreS2 and S proteins. The HBV genome is 
encapsulated by the core protein. On the right: Non-infectious filamentous and spherical 
particles. Figure according to Gerlich (Gerlich et al., 2009). 
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1.3. The viral genome  
 
The HBV genome is approx. 3.2 kb long and is one of the smallest replication-competent 
virus genomes. HBV is classified into eight genotypes A-J, each with a distinct geographic 
distribution (Lin et al., 2011). The partially double stranded DNA genome of HBV contains a 
full length negative sense strand that is complementary to pregenomic viral RNAs. The viral 
genome encodes four overlapping open reading frames for the transcription of surface, core, 
polymerase, and X proteins. The viral polymerase (P) protein is covalently attached to the 5` 
end of the minus strand (Gerlich et al., 1980). The virion DNA is linear but arranged as a 
circle with a specific gap or nick in the negative-sense strand (Gerlich et al., 2009).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Genome scheme of HBV. 
The four encoded translational reading frames of the DNA sequence are C-core, S-surface 
proteins, P-polymerase, and X protein. The core and polymerase open reading frames are in 
the same orientation, but the S translational reading frame overlaps these reading frames. 
Figure according to Gerlich (Gerlich et al., 2009). 
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1.4. The viral replication cycle  
 
The Hepadnaviral replication takes place in hepatocytes. Other types of cells have been found 
to allow HBV replication to a lesser degree (Parvaz et al., 1987; Pontisso et al., 2008). Virus 
entry of Hepadnaviridae into hepatocytes is dependent on N terminus of the large (L) surface 
antigen (Glebe, 2006; Leistner et al., 2008; Schulze et al., 2010; Zhang et al., 2011a). 
Recently, HBV attachment and entry into hepatocytes has been visualized (Meier et al., 2013; 
Schieck et al., 2013). Simultaneously another group of researchers identified the sodium 
taurocholate cotransporting polypeptide (NTCP) as a hepatocyte receptor, which allows the 
entry of the virus (Yan et al., 2012; Zhong et al., 2013). After viral entry the capsid moves to 
the cell’s nucleus where the viral nucleic acid is released and a covalently closed circular 
(ccc) DNA formed. This plasmid-like DNA serves as template for transcription of viral RNAs 
(Bock et al., 1994). The transcripts from the cccDNA consist of: Two species of 3.5 kb long 
RNAs (pregenomic and precore) and the 2.4 kb, 2.1 kb and 0.7 kb long subgenomic RNAs 
(Liang, 2009). After transport to the cytoplasm the viral RNAs are translated by ribosomes to 
core, the surface proteins (S, M and L) and the X-protein. The surface proteins differ in their 
N-terminal sequences that are longer in case of L and M protein. They consist of a common S 
domain, M consist of additional preS2 and L additional preS2 and preS1 domains. These 
proteins assemble the viral envelope. Further, surface proteins can be secreted as non-
infectious filamentous and/or spherical particles that do not contain a functional nucleocapsid. 
The pregenomic (pg) RNA is both a template for core and for viral DNA-polymerase. The 
viral DNA-polymerase binds the pg RNA and induces the packaging of pg RNA into the 
already translated core protein. The core protein forms the basis of the capsid and also plays 
an active role in binding and packaging of pg RNA (Bock et al., 2001). After transcription of 
pg RNA to the minus strand DNA and subsequent positive strand synthesis, the capsid 
interacts with L-proteins and finally acquires the envelopment of core with the surface 
proteins. Finally, viral particles are secreted into the extra-cellular milieu via multivesicular 
bodies. 
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Figure 3: Live cycle of HBV.  
Figure according to Gerlich (Gerlich et al., 2009). 
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1.5. Clinical course and immune pathogenesis of HBV infection  
 
Hepatitis B virus is transmitted by contact with contaminated blood or other body fluids (i.e. 
semen and vaginal fluid). The incubation time can vary from about 30 to 180 days. HBV 
persists for widely variable periods of time. 65% of infections in young persons and adults are 
asymptomatic. In 35% the infection results in liver inflammation. The symptoms of the acute 
hepatitis are icterus, enlarged liver and occasionally disruption of blood development. The 
symptomatic acute infection persists normally two to three weeks. After this period the 
infection cures or converts into a chronic infection in 5 to 10% of all infected persons (WHO, 
2002). However, infection in new-borns drifts in 90% to a chronic disease. In young children 
chronic infection occurs in 50% of infections. 60% of the chronically infected persons remain 
asymptomatic with a chronic persistent hepatitis (CPH). The remaining chronic infections 
result in chronic active hepatitis (CAH). CAH can spontaneously be transformed to CPH 
(Modrow et al., 2003). 
After entrance into the body the virus reaches the liver and infects hepatocytes. Activation of 
the innate immune response to HBV is weak, however, viral clearance and liver pathology are 
largely mediated by the adaptive immune response (Chisari et al., 2010) Prior to virus 
replication in hepatocytes most probably Kupffer cells recognize HBV patterns and activate 
NF-ĸB and proinflammatory cytokines (Hosel et al., 2009). Further, interleukin-6 seems to be 
responsible for suppression of HBV early after infection of the hepatocytes while it activates 
mitogen-activated protein kinase (MAPK) and c-Jun N-terminal kinase (JNK), which down 
regulate expression of hepatocyte nuclear factor 4α (HNF4α) and HNF1α, the key 
transcription factors regulating HBV gene expression (Quasdorff et al., 2008). However, the 
lack of interferon response in the early phase of infection is responsible for the typical 
widespread expansion of HBV in the liver. In vivo experiments in transgenic mice showed, 
that interferon-α and -β reduce expression of HBV genes in the early infection phase 
(Wieland et al., 2000). 
 
Disease pathogenesis and viral clearance are largely mediated by the adaptive immune 
response. Adaptive immune response, particularly the HBV-specific CD8 T cell response, is 
strong and multispecific in patients with self-limited infection, but usually weakly detectable 
in patients who develop chronic HBV infection (Chisari et al., 2010; Das et al., 2010). 
However, a recent study suggests that induction of effective CD8 T cell specific immune 
response to HBV is dependent on early CD4 T cell priming which might be regulated by the 
size of viral inoculum (Asabe et al., 2009). In acute hepatitis infection HBV is detectable 
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already in the incubation period. Interferons up regulate the expression of major 
histocompatibility complex (MHC) class I antigens on the cell surface which allows detection 
and elimination of infected cells. 
 
The MHC class II restricted immune response is foremost directed to the capsid proteins 
(HBcAg and HBeAg). The immune response to HBsAg is lower than to capsid proteins. B-
cells response to HBcAg and to a later time point to the large, the middle and the small 
surface proteins. Neutralizing antibodies (anti-HBs) to the virus block the spread of HBV and 
infection of hepatocytes. These antibodies to HBsAg also protect from reinfection with the 
virus (Modrow et al., 2003). 
The chronic HBV infection occurs, mainly, due to the lack of HBV specific adaptive T-cell 
immune response and lack of HBsAg specific humoral immune response. 
 
1.6.  Diagnosis of acute and chronic HBV infection  
 
The diagnosis of HBV infection is based on clinical, biochemical, histological and serologic 
findings. The interpretation of these findings is essential for the diagnosis of the various 
clinical forms of HBV infection. Table 2 gives an overview of serological and virological 
markers and their interpretation (Liang, 2009). 
 
Table 2: Hepatitis B virus serological and virological markers 
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The typical course of serological markers in acute HBV infection is shown in figure 4A. 
HBsAg is the first serological marker of acute HBV infection and is generally detectable after 
infection from week six on. From week eight on anti-HBc-IgM and HBeAg are almost 
present. IgG antibodies against HBcAg can first be detected after the peak of viraemia and at 
the time point of increasing transaminases. The first diagnostic parameters of the recovery 
from infection are reduction of viral load and short afterwards reduction of HBsAg and 
HBeAg in peripheral blood (Gerlich et al., 2009). 
The chronic HBV infection starts with similar serological pattern as the acute disease (Fig. 4). 
However, chronically infected patients do not lose HBV DNA, and rarely HBsAg and 
HBeAg. HBsAg is useful for diagnosis of transition from acute to chronic infection. 
Persistence of HBsAg over six months confirms the diagnosis of chronic HBV infection. The 
HBV DNA is a marker of active HBV replication in acute and chronic HBV infection. The 
amount of HBV DNA detected by quantitative PCR is an indicator of infectiousness. Anti-
HBc is a good parameter to determine the infestation rate of HBV in a population. So far 
HBcAg is not used as part of a vaccine and is only detectable after infection with HBV. 
 
 
Figure 4: Clinical course and serological profiles of acute (A) and chronic (B) HBV-infection. 
Figure according to Liang (Liang, 2009).  
 
1.7. Therapy of chronic HBV infection  
 
Chronically HBV infected patients belong to a risk group to develop liver cirrhosis and in 
sequel hepatocellular carcinoma (HCC). High load of HBV DNA is associated with 
development of cirrhosis and HCC. HCC occurs predominantly in countries with a high 
prevalence of HBV. The first therapy of chronic HBV infection is treatment with interferon-
alpha. Particularly, the pegylated form of interferon-alpha acts as deposit and is the preferred 
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form for treatment. 30% of the chronic infections can be treated successfully with this 
medication. Therefore therapy with peg-IFN has become the first-line treatment (Takkenberg 
et al., 2010). 
 
Further, treatment with nucleoside analogues (NUCs) has been currently approved. The most 
frequently used nucleoside analogue in the past was lamivudin (3TC; 2’,3’-Dideoxy-3’-
Thiacytidin). Lamivudin is an inhibitor of pyrophosphorolyse activity of the viral reverse 
transcriptase and is used and developed for treatment of HIV infection. In contrast to 
retroviral infection the HBV pregenome RNA is transcribed into the DNA before secretion of 
the virions into the plasma. Due to the half-life of particles in the plasma of about 1.5 days, 
the reduction of the viral load can be reached very fast after medication. However, medication 
with NUCs cannot eliminate the virus due to the persistence of HBV cccDNA in the nucleus 
of hepatocytes. Further, only 10 to 20% of patients lose HBeAg one year after therapy. The 
same proportion of patients develops resistance to lamivudin due to mutation in the YMDD 
motif of the HBV polymerase gene and therefore a viral rebound occurs. The emergence of 
resistance to lamivudin led to development of new less resistance susceptible NUCs like 
entecavir and tenofovir (Tab. 3) (Schaefer et al., 2009). Tenofovir and entecavir have a 
markedly lower risk of resistance than the other approved NUCs, therefore these drugs are 
preferentially used as a first-line therapy today.   
 
Table 3: Approved nucleosid analogues (NUCs) for HBV treatment 
 
 
A final therapeutic option for patients with carcinoma and liver failure due to HBV is liver 
transplantation. The therapy of chronic HBV infected patients after liver transplantation is 
difficult due to immunosuppressive medication. However, these patients have to be treated 
with NUCs and immunoglobulins directed against HBsAg. The reinfection of the new liver 
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can nevertheless occur due to circulating infectious virus particles in the peripheral blood (Lai 
et al., 1998; Tillmann et al., 1999). 
 
1.8.  Vaccines against Hepatitis B 
 
In the 1980s spherical and filamentous HBsAg particles purified from plasma of HBsAg 
carriers were used as a vaccine against HBV (Maupas et al., 1976). The plasma of the chronic 
carriers was inactivated to avoid the potential risk of residual infectious HBV, HIV particles 
or infection with other pathogens.  The vaccine consisted of 22 nm HBsAg particles.  
Second generation vaccines are recombinant non-glycosylated small surface proteins (S) 
produced in yeast (McAleer et al., 1984). These vaccines have been shown to be highly 
immunogenic and are used in vaccination programs in more than 150 countries worldwide. 
However, approximately 4-8% of vaccinees in the first three decades of life, and over 10% in 
the fourth decade and onwards do not seroconvert following immunization (McAleer et al., 
1984; Andre, 1990).  
Recently, third generation vaccines containing not only the S protein, but also the middle (M) 
and the large (L) surface proteins has been developed (Hourvitz et al., 1996). These vaccines, 
produced in mammalian Chinese hamster ovary (CHO) cells, have been shown to induce an 
immune response, which occurs earlier and is stronger than that induced by S alone (Raz et 
al., 1996). Even in many so called “non-responders” to S protein a protective immune 
response was induced (Rendi-Wagner et al., 2006).  
 
1.9. Future vaccines 
 
In the present the majority of persons vaccinated against hepatitis B successfully respond to 
vaccination, however approx. 5% of persons are non-responders. This situation clearly 
emphasizes the need of improved prophylactic preparations that would prevent spread of 
HBV. Simultaneously, new optimized preparations have to be examined for their sufficiency 
in therapeutic vaccination of individuals suffering from chronic hepatitis B infection. The 
preS1 region of HBV large surface antigen is involved in attachment and entry of HBV into 
hepatocytes (Fig. 5). Immunization of mice with PreS1 induced antibodies, which neutralize 
HBV in tissue culture (Glebe et al., 2005). Therefore, inclusion of preS1 sequence of the 
hepatitis B virus (HBV) envelope into immunogens should improve the efficacy of the 
vaccination, inducing a wider spectrum of antiviral antibodies. In support of this, it has been 
shown that anti-PreS antibodies appear early during HBV infection, before the detection of 
anti-hepatitis B surface antibodies (anti-HBs) (Neurath et al., 1986a; Neurath et al., 1986b; Le 
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Seyec et al., 1999; Maeng et al., 2000). Their appearance is usually followed by recovery 
from HBV infection. In contrast, anti-PreS antibodies are exceptionally rare in chronic 
hepatitis B (Neurath et al., 1986a; Maeng et al., 2000; Zhang et al., 2011b).  
 
 
 
 
 
 
 
 
 
 
Figure 5: Topologic model of HBsAg at the endoplasmic reticulum membrane.  
The binding site of PreS1 region into hepatocytes is indicated. Figure according to Gerlich 
(Gerlich et al., 2009). 
 
 
In the past, a new type of vaccines, which uses virus like particles (Fig. 6), was developed. 
One of such vaccines is the highly immunogenic HBV core protein (HBcAg) a very potent 
protein for induction of cellular immune response against HBV (Borisova et al., 1990). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Topologic model of HBV core particle.  
The particle (left) consists of 120 core protein dimers (right). The major immunodominant 
region (MIR) is indicated. Figure according to Pumpens (Pumpens et al., 1995). 
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However, antibodies to HBcAg do not protect against HBV infection (Ferrari et al., 1988; 
Jung et al., 1995). 
This highly immunogenic HBcAg particle (120 core dimers = 1 core particle) can be used as a 
carrier of foreign B- and T-cell epitopes to enhance the immune response (Milich et al., 
1997a; Milich et al., 1997b). Therefore, the main advantage of chimeric HBcAg particles is 
the induction of high titres of antibodies and simultaneously vigorous T-cell mediated 
immune responses (Pumpens et al., 2001). Therefore such particles are a promising approach 
for creation of a new type of HBV-specific immunogen.  
In the past the PreS1 fragment of HBsAg, which is able to induce virus-neutralizing 
antibodies (Deepen et al., 1990; Pizarro et al., 2001; Glebe et al., 2003), was inserted into the 
HBcAg particle (Lachmann et al., 1999). The resulting chimeric virus like particles (VLPs) 
containing PreS1 increased the immune response to HBV in mice. In these experiments, 
however, the ability of the chimeric particles to provide protection against a challenge with 
HBV was not examined. 
 
1.10. Animal models in Hepatitis B research 
 
Chimpanzees are the only animals fully permissive for HBV infection. Conversely, their use 
for research purpose is severely limited by the high costs and strong ethical constrains. In 
general, most of progresses in hepatitis B virus research are based on infection studies with 
HBV-related animal models. The Woodchuck and its Woodchuck hepatitis virus (WHV) 
infection serves as an important model for pathogenesis and immune reactions caused by 
HBV in humans (Roggendorf et al., 2007; Roggendorf et al., 2010). Most preclinical testing 
of antiviral treatment against HBV is done with WHV-infected woodchucks (Lu et al., 2008). 
WHV and HBV are members of the virus family Hepadnaviridae (Lu et al., 2001) which 
cause persistent infections of hepatocytes, persistent viremia, and antigenemia.  
The genome of WHV is, similar to HBV, circular and partial double stranded with a length of 
approximately 3.3 kb. The WHV envelope proteins also consist of the small, the large, and 
the middle proteins. The WHV genome is encapsulated by the nucleocapsid (core) protein 
(WHcAg). Similar to HBV core the WHV core was already shown to induce a strong humoral 
and cellular immune response. Furthermore, protection against the challenge was observed in 
woodchucks immunized with WHcAg (Menne et al., 1997; Menne et al., 1998). Recently, 
VLPs based on the WHcAg were described (Billaud et al., 2005a).  
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However, neutralizing antibodies to the PreS1 epitopes of the WHV were still not examined. 
If a protective effect is demonstrated, this type of chimeric VLPs might be considered as a 
prototype of a new HBV prophylactic and/or therapeutic vaccine for the use in humans. 
 
1.11. Transfer of cells of the immune system by transplantation  
 
In 1942 Landsteiner et al. reported for the first time that specific immunity was transferred 
from one patient to another by lymphocyte transmission (Landsteiner, 1942). From that time 
on, adoptive immune transfer was described by transfer of lymphocytes from mesenteric 
lymph node cells, gut intraepithelial lymphocytes, peritoneal cells, spleen cells and bone 
marrow cells (Ghadirian et al., 1983; Iverson et al., 1983; McDonald et al., 1996). 
In recent years studies show successful adoptive transfer of immunity against infectious 
diseases, like HBV in bone marrow transplant patients (Peters et al., 2000; Kupeli et al., 2002; 
Serap et al., 2010). In 1995 Shouval et al. systematically analysed adoptive transfer in mice in 
which immunity against HBV was transferred by bone marrow transplantation from the donor 
to the recipient (Shouval et al., 1995). The same group showed in an initial clinical study (Ilan 
et al., 1993) that 12 bone marrow transplanted recipients who were HBV-carriers recovered 
from viral infection after receiving bone marrow from healthy donors immune to HBV (anti-
HBc+/anti-HBs+). Before transplantation the recipients had been anti-HBs negative. Post-
transplantation they developed protective anti-HBs levels of above 10 mIU/ml antibodies. The 
patients remained protected from HBV and none of them suffered from acute HBV infection 
during the follow-up period of 7 months. An immune transfer via hematopoietic stem cell 
transplantation could also be observed after electively vaccinating donors against HBV 
(Lindemann et al., 2003a). Dahmen and co-workers systematically analysed the adoptive 
transfer of immunity against the hepadnaviral infection by liver transplantation in the rat and 
the woodchuck model (Dahmen et al., 2003a; Dahmen et al., 2003b; Dahmen et al., 2004). 
Results of this study showed, that the transfer of immunity from donor to recipient by liver 
transplantation is feasible.  
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1.12. Aim of the thesis 
 
Liver transplantation is often the ultimate option of therapy for patients with cirrhosis due to 
chronic hepatitis B virus (HBV) infection. Due to organ shortage the living liver donation 
between relatives increased steadily in the past and represents one cohort of liver donation. 
However, prevention of reinfection with HBV by HBV Immunoglobulin is cost-intensive and 
in several cases not effective.  
The transfer of HBV immunity in rats after liver transplantation and subsequent experiments 
in woodchucks showed the suppression of severe reinfection in chronically infected liver 
recipient animals after transplantation of the liver from uninfected animals to chronically 
WHV infected animals.  
These findings encouraged us to examine the transfer of immunity to HBV from living donor 
to a chronically HBV infected recipient. Donors and recipients undergo a transplantation 
evaluation program within 1-2 months. However, this time is too short for inducing suitable 
immune response to HBV with a standard vaccination scheme (6 months).  
Therefore, the first aim of this study was to establish a short time immunization protocol to 
induce high HBV specific B and T-cell response with a new vaccine which contains PreS1, 
PreS2 and S protein in healthy volunteers within a short period of 1-2 months.  
The second aim was to immunize living liver donors using the short time immunization 
protocol and to examine the transfer of immunity from immunized donors to HBV negative 
recipients and chronic HBV infected recipients after transplantation. 
The aim of the third part of this thesis was to improve a current vaccine to HBV by including 
PreS1 protein of HBV to the vaccine which induces high titer of antibodies to PreS1 which 
inhibits binding of HBV to its receptor NTCP. Therefore virus like particles (VLPs) 
composed of the WHV core protein with insertions of PreS1-derived peptides should be 
generated. The humoral immune response against the VLPs should be examined in mice and 
protection can be tested in the preclinical animal model (woodchuck). 
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2. Materials and Methods 
 
2.1. Study Population 
 
2.1.1. Patients  
 
This study was approved by the institutional review board (AZ: 03-2234).  
For evaluation of the short time immunization protocol 30 volunteers were immunized against 
HBV. All 30 volunteers provided written informed consent. 
46 living liver donors were immunized against HBV and 14 liver recipients received the liver 
from an immunized donor. All 46 living liver donors and 14 liver recipients provided written 
informed consent. All vaccinations in humans were performed by Melanie Fiedler and 
Monika Lindemann. 
  
2.1.2. Animals  
 
For immunization experiments BALB/cJ (H-2d) mice were used. They were kept under 
standard pathogen-free conditions in the Institute of Virology, University Duisburg-Essen. 
Experiments were conducted in accordance with the Guide for the Care and Use of 
Laboratory Animals (NRC, 2011) and were reviewed and approved by the local Animal Care 
and Use Committee (Animal Care Center, University of Duisburg-Essen, Essen, Germany), 
and the district government of Düsseldorf, Germany. For immunization and taking blood mice 
were anesthetized with Isoflurane. 
 
2.2. Chemicals  
 
All chemicals, unless stated otherwise, were purchased from Gibco (Karlsruhe, Germany), 
Merck (Darmstadt, Germany), Roth (Karlsruhe, Germany) and Sigma (München, Germany). 
 
2.2.1. Commercial kits and reagents 
 
Qiagen Plasmid Mini Kit   (Qiagen, Germany) 
Qiagen Plasmid Midi Kit    (Qiagen, Germany) 
QiaQuick Gel Extraction Kit   (Qiagen, Germany) 
TOPO™ TA Cloning® Kit (Version R) (Invitrogen, Germany)  
Taq DNA Polymerase (5U/μl)  (Promega GmbH, Germany) 
10x Reaction buffer    (Promega GmbH, Germany) 
MgCl2 (25mM)    (Promega GmbH, Germany) 
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dNTP (10mM)    (Promega GmbH, Germany) 
100 bp-DNA-Ladder plus   (Fermentas, Germany) 
M-MLV RT 5x Reaction buffer   (Promega GmbH, Germany) 
M-MLV Reverse Transcriptase (200U/μl) (Promega GmbH, Germany) 
 
2.2.2. Cell culture conditions  
 
Human PBMCs were cultured in RPMI 1640 medium. Before usage 10% human serum 
(separated from pooled sera of blood donors), 10 mg/ml penicillin/streptomycin (PAA 
Laboratories, Austria) and 2mM L-glutamine were added. Mice cells isolated from spleen 
were cultured in RPMI 1640 medium. Before usage 10% fetal serum albumin, 10 mg/ml 
penicillin/streptomycin (PAA Laboratories, Austria) and 2mM L-glutamine were added. 
 
2.2.3. Peptides and proteins 
 
The HBV PreS1 peptide (aa 1-108) and the HBV S-protein (227 aa) were purchased from 
Acris Antibodies (Hiddenhausen, Germany). The HBV S, M and L protein containing 
suspension (produced in CHO cells) was kindly provided by Berna Biotech (Bern, 
Switzerland). The WHV PreS1 peptide (aa 1-81) was a gift from Stephan Urban, Heidelberg.  
 
2.2.4. Plasmids 
 
WHV core particles were expressed using the PQE60 plasmid from Qiagen (Qiagen, 
Germany). Plasmids for PreS1-GST transformation and expression were purchased from 
Invitrogen (see table 4) using E. coli Expression System with the Gateway® Technology. 
Schematic maps of the plasmids were included into the appendix (see section 7.1).  
 
 
Table 4: Plasmids 
 
 
2.2.5. Bacterial strains 
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Bacterial strain E. coli JM 109 was used for transformation and expansion of the plasmid 
PQE60 and BL 21 for protein expression from the plasmid PQE60. For transformation of 
pENTR™/SD/D-TOPO® plasmid strain TOP 10 One Shot™ (Invitrogen, Germany) cells 
were used. The transformation of pDEST™ was performed using the bacterial strain DH5α™. 
For PreS1-GST expression E. coli strain BL21-AI™ One ShotR was used. Table 5 
summarizes the genotype of all used bacterial strains.  
 
Table 5: Bacterial strains 
 
 
2.2.6. Restriction enzymes 
 
Table 6 summarizes all enzymes, which were used for restriction of PCR products or/and for 
restriction of the plasmids. 
 
 
Table 6: Enzymes 
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2.2.7. PCR primers 
 
Table 7 summarizes all primers which were used in the PCR.  
 
Table 7: PCR-Primer 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.8. Instruments 
 
Instrument       Manufacturer 
Autoclave       Lautenschläger, Germany 
Cell culture incubator      Heraeus, Germany 
Gel electrophoresis box Medizintechnik, University Hospital Essen, 
Germany 
Electrophoresis PowerPack P25 Biometra, Germany  
ELISA-Reader SorinBiomedica, Italy 
Bioreader 2000  Biosys, Germany 
Imaging System GeneGeniusBio Synoptics, United Kingdom 
UV transluminator FLX-20M MWG-Biotech, Germany  
Light microscope Carl Zeiss AG, Germany 
Freezer -20 °C Liebherr, Germany 
Cell culture hood HeraSafe  Heraeus, Germany 
Microwave Panasonic, Germany 
Thermocycler Mastercycler gradient Eppendorf, Germany 
Thermocycler PxE0.5 Thermal Cycler    ThermoScientific, USA 
LightCycler 2.0  Roche, Germany 
PH meter MP 220 pH Meter  Mettler Toledo, Germany 
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Spectrophotometer Gene Quant pro Amersham Bioscience, USA 
Pipettes Eppendorf, Germany; Gilson, USA 
Vortex Genie2 Scientific Industries, USA 
Scales  Sartorius AG, German 
Water bath Julabo, Germany 
Centrifuge 5415C, 5810 Eppendorf, Germany 
Megafuge 1.0R Heraeus, Germany 
 
2.2.9. Vaccines against Hepatitis B  
 
Healthy volunteers (n=15) and living liver donors (LLD) were vaccinated using Sci-B-Vac 
(kindly provided by SciGen Ltd., Singapore, Singapore). The standard vaccine HBVAXPRO
®
 
(Sanofi Pasteur MSD, Frankfurt, Germany), containing only S protein, was used for 
vaccination of healthy volunteers (n=15) and of living liver donors with persisting vaccine 
derived immune response against HBV. The distribution of L, M and S Protein in Sci-B-Vac 
and HBVAXPRO
®
 vaccine is shown in figure 7.     
 
 
Figure 7: Distribution of PreS1, PreS2 and S protein in Sci-B-Vac and HBVAXPRO® 
vaccine.  
(a) Distribution of PreS1, PreS2 and S protein in Sci-B-Vac vaccine produced in Chinese 
hamster ovary cells (CHO). (b) S protein in yeast derived HBVAXPRO® vaccine. 
 
2.3. Methods 
 
2.3.1. Immunization of healthy volunteers  
 
In total 30 healthy volunteers were randomly immunized either with 20 µg Sci-B-Vac (n = 15; 
female: 8, male: 7) or a German standard HBV vaccine HBVAXPRO
®
 at the recommended 
dose of 10 µg (n = 15; female: 9, male: 6) four times at two-week intervals. We examined the 
humoral (anti-HBs titer) and cellular (ELISpot, proliferation assay) immune responses before 
each administration, four weeks after the last immunization, and again one year after 
immunization. 
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2.3.2. Immunization of living liver donors  
 
Potential LLD (n = 46) received immunizations either with Sci-B-Vac (n = 39), a third 
generation vaccine up to 5 times at least biweekly with a 20 µg dose or booster immunizations 
with HBVAXPRO
®
 (n = 7), a second generation vaccine at the recommended dose of 10 µg. 
Humoral and cellular immune responses in donors were determined by anti-HBs titer, 
proliferation assay, and IFN-γ ELISpot after immunization and in LLD also before 
transplantation.  
 
2.3.3. Treatment and monitoring of immune responses in recipients  
 
In recipients (n = 14) HBV specific humoral and cellular immune responses were measured 
prior to and after transplantation at least monthly by the same assays. To prevent rejection of 
the graft, recipients were treated with different immunosuppressive drugs. Usually 
cyclosporin A or tacrolimus, mycophenolate mofetil and prednisone were administered. The 
reduction of immunosuppressive medication differed due to the recipient’s requirements. 
Chronically HBV infected patients received, in addition, passive immunoprophylaxis using 
Hepatitis B specific immunoglobulin (HBIg Hepatect, Biotest, Dreieich, Germany). HBIg was 
administered intravenously using a previously described protocol (Beckebaum et al., 2003). 
Combination of this medication with the nucleoside analogue lamivudine was indicated, when 
HBV DNA was detectable after transplantation. 
 
2.3.4. Immunization of mice  
 
BALB/cJ mice aged 6–8 weeks were immunized subcutaneously using 20 µg of either 
WHcPep3, WHcPep4, WHcPep6 and WHV PreS1 peptide (aa 1-81), each vaccine emulsified 
in incomplete Freund’s adjuvant (IFA; Sigma, Deisenhofen, Germany). Mice received three 
immunizations in a time interval of two weeks and were sacrificed three weeks after the last 
immunization for determination of serum antibodies (1:100 dilution) against WHV PreS1. 
Cellular immune response was measured using WHV PreS1-GST protein for stimulation in a 
proliferation assay.  
 
2.3.5. Proliferation assay with human PBMCs  
 
The proliferation assay was performed in round bottom microtiter plates with 2.5 x 10
5
 
PBMCs per 200 µl culture by stimulation with the same antigen concentrations, which were 
already described for the ELISpot assay. Cell culture conditions and measurement of [3H] 
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thymidine uptake followed a protocol described previously (Lindemann et al., 2002). For the 
evaluation of proliferation assays median values of triplicate cultures were considered. The 
stimulation index (SI) was defined as the quotient of HBV-specific and autologous 
(unstimulated) proliferative responses. Values of SI > 2.5 were defined as positive as 
described before (Lindemann et al., 2002). 
 
2.3.6. Interferon-γ ELISpot  
 
PBMCs from heparinized blood were separated by Ficoll–Hypaque™ (Amersham Pharmacia 
Biotech, Sweden) density gradient centrifugation. 4 x 10
5
 PBMCs in 200 µl culture volume 
were pre-incubated with 1 µg/ml S, M and L protein, or 1 µg/ml L protein fragment (108 aa), 
or 0.5 µg/ml of the small S protein (227 aa) in round bottom microtiter plates (Becton 
Dickinson Labware, Germany). After 48 h the cells were transferred from round bottom 
microtiter plates to pretreated ELISpot plates. 
Pretreatment of ELISpot plates: Wells of the MultiScreen-HA ELISpot plates (MAHAN4550, 
Millipore, Bedford, MA, USA) were coated for 2 h with antibody specific for human IFN-γ at 
37°C or overnight at 4°C. Thereafter, plates were washed 3 times with PBS and blocked for 
1 h at room temperature with 10% human serum in RPMI-medium.  
Detection of IFN-γ producing cell clones: After 48 h cells were discarded; plates were washed 
6 times with 0.05% Tween 20 containing PBS solution and incubated for 1 h with human 
IFN-γ biotinylated second antibody. Subsequent cytokine production of IFN-γ was detected 
by a solid phase ELISA as described previously (Lindemann et al., 2003b). Numbers of spots 
were analyzed by the Bioreader 2000 (Biosys, Germany). For the evaluation of IFN-γ 
production median values of triplicate cultures were considered. ELISpot results were 
generated as HBV-specific minus the autologous (unstimulated) values. Negative values were 
set as zero. Before the first immunization cellular immune responses following stimulation 
with HBV antigens were measured. The mean value plus the sum of three standard deviations 
(SD) was set as threshold to define unspecific IFN-γ production. An ELISpot response among 
the immunized groups was considered positive if a value of spots  9 was achieved after 
PreS1 (aa 1-108) stimulation (value of spots ≥ 10 after S, M, L and of spots ≥ 16 after S 
stimulation). 
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2.3.7. HBV specific serology  
 
Serum was separated by centrifugation and HBsAg, anti-HBc, HBeAg, and anti-HBs were 
measured by Chemiluminescent Microparticle Immunoassay (Architect System, Abbott 
Laboratories, Wiesbaden, Germany) following the manufacturer’s instructions. The detection 
limit of the anti-HBs titer is 10 IU/l. 
 
2.3.8. WHV specific serology  
 
Serum was separated by centrifugation and anti-WHV PreS1 antibodies of mice sera were 
detected by enzyme-linked immunosorbent assay (ELISA). Therefore MicroELISA plates 
(Maxisorp, Nunc, Germany) were coated with 150 ng of the PreS1-GST protein per well in 50 
µl 0.1 M sodium carbonate buffer (pH 9.5) at 4°C. Mice sera were diluted 1:100 in loading 
buffer (PBS supplemented with 3% BSA and 2% Tween 20) and added to the PreS1-GST 
protein-coated wells. The antibodies were incubated for 2 h at 37°C followed by four washes 
with 0.05% Tween 20 in PBS. Bound antibodies were detected using HRP-conjugated anti-
mouse IgG antibodies (cat. no. 02067E, PharMingen, Germany) at a dilution of 1:2000 
followed by incubation with o-phenylendiamine and 2x HCl (cat. no. 6172-24, Abbott, 
Germany) in PBS (pH 6.0). The reaction was stopped by 1 M H2SO4 and the extinction was 
determined at 492 nm. 
 
2.3.9. Administration of Immunoglobulin to HBsAg (HBIg)  
 
Patient 1 received 1,000 IU anti-HBs (HBIg) per day intravenously for 21 days. These 
antibodies were diluted in approximately 3.5 l plasma of a 75 kg heavy recipient and resulted 
in an anti-HBs titer of 286 IU/l. This value could only be an assumption to the real titer found 
in individual patients; however, it seems to be accurate enough to roughly calculate the 
expected HBIg derived anti-HBs titers. The portion of the HBIg derived antibody titer was 
calculated considering an anti-HBs half-life of 21 days (Partovi et al., 2001) and using 
generally approved formulas (Birkett, 2002). Additionally, the recipients required fresh frozen 
plasma during the surgical treatment that contained small amounts of anti-HBs. Therefore, 
plasma derived anti-HBs was measured and the expected anti-HBs titer decay was calculated 
as described above.  
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2.3.10. Qualitative and quantitative detection of HBV DNA  
 
HBV DNA was extracted from 200 μl of serum using QIAamp blood kit (Qiagen, Germany). 
The qualitative HBV DNA detection was performed with the Artus HBV LC PCR Kit 
(Qiagen, Germany) using the LightCycler 2.0 (Roche Diagnostics GmbH, Germany) 
following the manufacturer’s instructions. Here, the detection limit is 100 IU/ml. The 
quantification was performed with the VERSANT HBV DNA 3.0 Assay (bDNA) (Siemens, 
Germany) on the BAYER VERSANT 440 MOLECULAR SYSTEM (Siemens, Germany) 
following the manufacturer’s instructions. The detection limit of HBV DNA is 357 IU/ml.  
 
2.3.11. Determination of HBV subtype by PCR  
 
HBV DNA was extracted from serum as already described and subjected to PCR 
amplification for the HBV genome region comprising the s gene. Ten μl of extracted DNA 
were amplified in a 50 μl reaction mixture with the primers 6DC (nt 131-148) and S7D (nt 
845-825). The nucleotide positions of primers are numbered according to a published 
complete HBV sequence (GenBank accession number AY220698). The PCR product was 
cloned into pCR®2.1-TOPO vector (Invitrogen, Germany) and subjected to DNA analysis. 
The subtype of HBV isolates was determined according to the HBsAg sequence.  
 
2.3.12. Computer based structure prediction  
 
3D-JIGSAW is an automated system based on the analysis of homologues of known 
structures and used to build three-dimensional models of proteins (Bates et al., 2001). This 
software was applied to identify the MIR of the WHcAg. The structure prediction was made 
by comparison with the known structure of the HBV core protein (PDB-ID: 1QGT). The 
protein was visualized using the UCSF Chimera package (Pettersen et al., 2004) from the 
Resource for Biocomputing, Visualization, and Informatics at the University of California, 
San Francisco (supported by NIH P41 RR-01081).  
 
2.3.13. Construction of vectors containing core and preS1 epitopes  
 
The pQE60 vector was used for the expression of the truncated WHcAg (149 aa residues) 
(NCBI accession no. J04514) inserted between the NcoI-BglII restriction sites (kindly 
provided by Menji Lu, Essen, Germany). The Bsp119 insertion site between the amino acids 
78 and 79 of the truncated WHcAg (149 aa residues) was kindly provided by Melanie Fiedler, 
Essen, Germany. Six overlapping fragments of the PreS1 protein (149 aa in length) gene were 
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generated by PCR using WHsAg (NCBI accession no. M19183) gene sequence as a template, 
and six preS1 specific pairs of primers (see table 7: Pep1-Pep6), which additionally included 
the Bsp119 restriction site. Table 8 summarizes the PCR conditions for PCR products 
PCRPep1-PCRPep6. 
 
Table 8: PCR conditions for PCR products PCRPep1-PCRPep6  
 
 
Each resulting PCR product (PCRPep1-PCRPep6) and the PQE60 vector containing the 
truncated WHcAg gene sequence modified with Bsp119 restriction site (Q60WHcBsp) were 
digested by the Bsp119 restriction enzyme and ligated with the T4 DNA ligase to create six 
new WHcAg constructs with the corresponding insertions. The correct reading frame of the 
inserts was verified by sequencing. The propagation and the purification of the plasmids 
(Qiagen, Germany) and the ligation reactions (Fermentas, Germany) were performed using 
commercial kits according to the manufactures instructions (Qiagen, Germany and Fermentas, 
Germany). The transformation of the plasmids into the BL21 E. coli strain allowed the 
expression of the corresponding protein under the control of the T5/Lac operon promoter.   
 
2.3.14. Protein expression, purification and capsid assembly  
 
E. coli was grown on a rotary shaker at 37°C until an optical density of 0.6-0.8 at OD540 was 
reached. The expression of the protein was induced by addition of 1 mM IPTG (isopropyl--
D-thiogalactopyranosidase) and additional incubation for 3 h. Cells were pelleted and lysed 
using the lysozyme-salt solution, aluminium oxide or sonication, respectively.  
The gentle lysozyme salt solution lysis was performed by dissolving the cells in one volume 
of the lysis buffer 1 (45 mM Tris/HCl pH 8, 4.5 mM EDTA pH 8, 0.45 µM 
phenylmethylsulfonylfluorid (PMSF)), two volumes of lysis buffer 2 (2 mg lysozyme per ml 
buffer 1) and one volume of lysis buffer 3 (0.4% Triton X-100 in buffer 1). Afterwards, the 
suspension was incubated for 10 min at -80°C and thawed in the cold. This step was repeated 
three times following addition of 1/6 volumes of DNase buffer (2 mg DNAse per ml 1 M 
MgCl2) and incubation for 30 min at 4°C.  
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The gentle method of cell disruption was performed by adding of 1 volume aluminium oxide 
powder to the frozen cells following crushing in a bowl for 30 min at 4°C. After addition of 3 
volumes of buffer 1 and 1/12 volumes of the DNAse buffer the suspension was incubated for 
30 min at 4°C. Sonication, the vigorous method of cell disruption was performed by addition 
of three volumes of buffer 1 and one volume of buffer 3 to the cells following 5 x 15 sec 
sonication (35 kHz) with a 45 sec distance between each. 
The protein was removed from debris by washing the pellet with PBS buffer or PBS buffer 
containing 0.45 M urea or 1.5 M urea. The resulting supernatant was precipitated overnight 
(4°C) with 20 to 33% of ammonium sulphate. The precipitated protein was recovered by 
washing with PBS buffer containing 0.1% Triton X-100 or Triton X-100 containing 0.45 to 
1.5 M urea. 5-7 ml of the supernatant were loaded on a 20-60% sucrose gradient and 
centrifuged overnight at 27,000 rpm, or on a Sepharose CL4B column, respectively, and 
eluted with PBS buffer without Triton X-100. The presence of WHV core protein in 2 ml 
fractions was tested by polyacrylamid gel electrophoresis (PAGE). Positive fractions were 
pooled and concentrated by ammonium sulphate precipitation overnight at 4°C as described 
above. Pellets were dissolved in PBS buffer or PBS buffer containing 0.45 M urea, 
respectively. The supernatant was dialyzed against 2000 volumes of PBS buffer and stored at 
-20°C in 50% glycerol or 50% sucrose, respectively.  
 
2.3.15. PAGE and Western blotting  
 
For the polyacrylamide gel electrophoresis (PAGE) bacteria were pelleted and the supernatant 
and the debris samples after lysis were suspended in the SDS-gel electrophoresis sample 
buffer (0.0625 M Tris-HCl pH 6.8, 2% SDS, 5% 2-mercaptoethanol, 10% glycerol, 0.1 mg/ml 
bromphenol blue). After heating at 100°C for 10 min the proteins were separated by 
Laemmli`s polyacrylamide gel electrophoresis with 15% running gel.  
Acrylamide stock:   29.1 g acrylamide; 0.9 g NN-methylenbisacrylamide;  
    Add water to 100 ml 
Loading-gel:    0.8 ml acrylamid stock; 3.6 ml water; 0.5 ml 1.875 M  
    Tris-HCl pH 8.8; 50 µl 10% Sodium dodecyl sulfate  
    (SDS); 5 µl Tetramethylethylenediamine (TEMED);  
    17 µl Ammonium persulfate (APS) 
Separating-Gel (15% SDS):  7.5 ml Acrylamid stock; 4.3 ml water; 3 ml 1,875 M;  
    Tris-HCl pH 8,8; 150 µl 10% SDS; 7.5 µl TEMED;  
    50 µl APS  
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Western blot was performed by transfer of the proteins into the nitrocellulose sheets (0.2 µm, 
Millipore, USA) and following incubation with anti-HBc mAb 14E11 (1:1,000), which 
recognizes HBcAg aa residues 136-144 (Skrivelis et al., 1993) and the WHcAg as well. After 
incubation for 1 h at room temperature the sheets were washed and then incubated for an 
additional hour with the anti-mouse IgG (1:1,000) peroxidase conjugate (Sigma, Germany). 
The reaction was developed by oxidation with o-dianisidine. 
 
2.3.16. Construction of vectors containing the PreS1-GST protein coding region  
 
PreS1 gene sequence (coding for aa 1-149) was generated by PCR using the gene sequence of 
WHsAg (NCBI accession no. M19183) as template and a preS1 specific primer pair PreS1 
pDest (see table 7). The PCR conditions are summarized in table 8. Differing from table 8, the 
PCR annealing temperature for generation of WHV preS1 was 58 °C. The PCR product PreS1 
was cloned into the pENTR™/SD/D-TOPO® vector. The correct reading frame of the insert 
was verified by sequencing. The ligation reaction, the propagation and the purification of the 
plasmid (Invitrogen, Germany) were performed according to the manufacturer’s instructions 
as well as the recombination reaction between the pENTR™/SD/D-TOPO® clone containing 
the PreS1 gene and the pDEST®24 vector. The ligation reaction, the propagation and the 
purification of the plasmid were also performed according to the manufacturer’s instructions. 
The E. coli DH5α strain was used for transformation of the plasmid. The cloning and protein-
expression procedure was shown in a flow diagram (Figure 8). 
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Figure 8: Flow diagram: Production of preS1-GST protein 
The correct reading frame of the insert was verified by sequencing. Transformation of the 
plasmid into the BL21-AI™ strain (Invitrogen, Germany) allowed the expression of the 
corresponding protein induced by L-arabinose. 
 
2.3.17. Purification of the PreS1-GST protein 
 
After expression the PreS1-GST protein was purified by Glutathione Sepharose™ 4B 
Media/GSTrap columns according to the manufacturer’s instructions (GE Healthcare Life 
Science, Germany). The purified protein was detected by SDS-gel electrophoresis and by 
Western blot as described above using an anti-GST antibody from goat (Amersham 
Biosciences, Germany). The second monoclonal antibody (anti-goat/sheep antibody 
peroxidase conjugated, Sigma, Germany) was used at a dilution of 1:5,000.  
 
2.3.18. Production and purification of PreS1-GST protein using electro-eluter  
 
The PreS1-GST specific band was cut out and was eluted from gel using electro-eluter. The 
membrane caps were soaked in protein elution buffer for at least 1 hour at 60°C.  
Elution buffer:   Tris-HCl:3 g (25 mM); Glycine: 14.4 g (192 mM);  
    SDS: 1 g (0.1%); Add water to 1 l 
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Thereafter the membranes were handled with gloves. The gel slice was loaded into the Model 
422 Electro-Eluter. The protein was eluted at 8 mA/glass for 4 hours. The sample was stored 
at -20°C. 
 
2.3.19. Electron microscopy  
 
Virus like particles (VLPs) were visualized by electron microscopy in the Biomedical Center 
of Riga (Latvia) in the Institute of Prof. Pumpens as described before (Skrastina et al., 2008).  
 
2.3.20. Statistical analysis  
 
The Mann-Whitney test was used to compare humoral and cellular HBV-specific immune 
responses between the Sci-B-Vac and HBVAXPRO
®
 group in healthy volunteers and WHV-
PreS1 specific humoral immune responses in mice. P values of < 0.05 were considered as 
statistically significant. 
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3. Results 
 
3.1. Immunization of healthy volunteers with HBV vaccine  
 
Healthy volunteers, 30 persons in total, were immunized four times with Sci-B-Vac (n = 15) 
or HBVAXPRO
® 
(control group, n = 15) at two-week intervals to determine B and T-cell 
immune responses to demonstrate whether Sci-B-Vac is suitable for short time immunization 
of living liver donors. Cellular immune responses (IFN-γ production and lymphocyte 
proliferation) were measured after stimulation of PBMCs with HBV surface proteins in weeks 
0, 2, 4, 6, and 10. One year after immunization cellular immune responses were measured in 
three individuals vaccinated with Sci-B-Vac or HBVAXPRO
®
, respectively. Side effects were 
not observed in any of the vaccinated volunteers.  
 
3.1.1. B-cell response in healthy volunteers  
 
We examined the humoral immune response (anti-HBs titer) prior to each and 4 weeks after 
the last immunization (Fig. 9). Anti-HBs was undetectable before the first immunization 
(week 0). In nine of fifteen volunteers immunized with Sci-B-Vac anti-HBs was detected 
already after the first immunization (week 2: geometric mean value [GMT] 16 IU/l). In 
contrast, only one volunteer of the control group showed a humoral immune response at this 
time point. After the second immunization (week 4) the GMT of the anti-HBs titer increased 
in both groups (Sci-B-Vac group 151 IU/l; control group 3 IU/l) compared to the mean values 
measured after the first immunization. At this time point all except for one volunteer of the 
Sci-B-Vac group showed a humoral immune response to HBV, whereas only five of fifteen 
controls became anti-HBs positive. After the third immunization antibody production was 
detected in all volunteers immunized with Sci-B-Vac with a GMT of 226 IU/l. In the control 
group 5/15 probands still presented without antibody production (GMT of anti-HBs titer 
12 IU/l). After the last immunization (week 10) all volunteers showed a humoral immune 
response (GMT in the Sci-B-Vac group 842 and 205 IU/l in the control group). One year after 
the first immunization we measured humoral immune responses in three volunteers 
immunized with Sci-B-Vac or HBVAXPRO
®
, respectively. The Sci-B-Vac vaccinated 
probands showed higher immune responses compared to those immunized with 
HBVAXPRO
®
 (GMT of anti-HBs 5,318 IU/l in the Sci-B-Vac group and of 95 IU/l in the 
control group). In summary, the short immunization protocol Sci-B-Vac induces significantly 
higher antibody titers after each of the four vaccinations as compared to volunteers 
immunized with HBVAXPRO
®
.  
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Figure 9: Humoral immune response after immunization with hepatitis B vaccines Sci-B-Vac 
(n = 15) and HBVAXPRO® (n = 15).  
The X-axis indicates time points of analysis and of immunizations (i). The Y-axis shows anti-
HBs titers in IU/l. The horizontal lines indicate geometric mean values. Volunteers 
immunized with [  ] Sci-B-Vac or [ ] the control vaccine. **P < 0.01 and *** P < 0.001. 
 
3.1.2. T-cell response (Lymphocyte proliferation) in healthy volunteers  
 
To determine cellular immune response to HBVAXPRO
® 
and Sci-B-Vac in the short time 
immunization protocol cells of the volunteers in both vaccinated groups were stimulated with 
S protein, with PreS1 region of the L protein or with simultaneous stimulation with S, M and 
L protein.   
After stimulation with S, M and L proteins both vaccinated groups did not display a 
proliferative response at week 2 (Fig. 10a). After the second immunization (week 4) cell 
proliferation became detectable in individuals immunized with Sci-B-Vac (mean value of 
SI = 9.5 vs. SI = 1.6 in the control group). The immune response increased after the third and 
fourth immunization (weeks 6 and 10) in both groups. It was significantly higher (P < 0.01) in 
volunteers immunized with Sci-B-Vac (mean values of SI = 17.7 and 26.5) than with the 
control vaccine (mean values of SI = 4.9 and 5.3). One year after immunization proliferative 
immune responses were still higher in Sci-B-Vac vaccinated individuals (SI = 15.5, 56.7, or 
108.2, respectively) compared to the control group (SI = 17.2, 6.7, or 2.4). Thus, individuals 
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immunized with Sci-B-Vac showed significantly higher proliferative responses to S, M and L 
proteins compared to volunteers immunized with the control vaccine.  
 
The PreS1 fragment of the L protein induced cell proliferation (Fig. 10b) in volunteers 
immunized with Sci-B-Vac after the last immunization (mean value of SI = 3.9 vs. SI = 0.9 in 
the control group). One volunteer immunized with HBVAXPRO
®
 was, unexpectedly, 
measured positive after the third immunization but he remained negative after the fourth 
immunization. As expected, no proliferative response was measured in the remaining 
volunteers of the control group. One year after immunization a proliferative immune response 
was still detectable in one of three Sci-B-Vac vaccinated probands (SI = 11.9). 
 
The cellular immune response was also measured after stimulation with the S protein 
(Fig. 10c). After the first and second immunization with Sci-B-Vac or the control vaccine 
(weeks 2 and 4) cell proliferation was found only in single volunteers. After the third 
immunization (week 6) proliferative responses were detected in a subgroup of volunteers 
immunized with Sci-B-Vac (mean value of SI = 2.0) and the control vaccine (mean value of 
SI = 4.2) and increased in the Sci-B-Vac group (mean value of SI = 2.7) after the last 
immunization (week 10). In contrast, cell proliferation slightly decreased in the control group 
at this time point (mean value of SI = 3.1). Thus, both groups showed similar cell 
proliferation after stimulation with the S protein alone. Of note, one year after immunization 
proliferative immune responses were still detected in three Sci-B-Vac (SI = 23.4, 7.5, or 3.2) 
and in two HBVAXPRO
® 
(SI = 13.6 or 3.6) vaccinated probands. 
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Figure 10: Cellular immune response (proliferation assay) after immunization with hepatitis B 
vaccines Sci-B-Vac and HBVAXPRO
®
.  
The X-axis indicates time points of analysis and of immunizations (i). The Y-axis shows the 
ratio between stimulated and unstimulated cells [stimulation index (SI)] after incubation with 
(a) L, M, and S proteins; (b) L protein fragment (108 aa); (c) S protein. The horizontal lines 
indicate mean values. Volunteers immunized with [  ] Sci-B-Vac or [   ] the control vaccine. 
*P < 0.05 and ** P < 0.01. 
 
3.1.3. T-cell response (IFN-γ production) in healthy volunteers  
 
In addition to lymphocyte proliferation we also observed IFN-γ production in both vaccinated 
groups by ELISpot assay. IFN-γ production was detected after stimulation with S protein or 
with PreS1 fragment of L protein or after simultaneous stimulation with S, M and L proteins.  
 
After simultaneous stimulation with S, M and L proteins (Fig. 11a) we detected IFN-γ 
production in 3 volunteers immunized with Sci-B-Vac (mean value: 6.7 spots versus 0.9 spots 
in the control group) already after the first vaccination (week 2). After the second 
immunization (week 4) IFN-γ production increased in this group (mean value 28.8 spots) and 
was detectable in the control group (mean value 8.5 spots) for the first time. Finally, 
volunteers immunized with Sci-B-Vac presented mean values of 57.1 and 71 spots after the 
third and fourth immunization (weeks 6 and 10). At these time points 20.1 and 42.2 spots 
were detected in the control group. Thus, Sci-B-Vac vaccinated volunteers showed earlier and 
significantly higher (P < 0.05) cellular immune responses after stimulation than controls did. 
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One year after immunization IFN-γ production in T-cells was still higher in the Sci-B-Vac 
vaccinated volunteers (67, 74, or 77 spots) compared to the control group (36, 40, or 56 
spots). 
 
The PBMCs were also stimulated with the PreS1 fragment of the L protein (108 aa). After the 
third and fourth immunization IFN-γ production was detected (Fig. 11b) at weeks 6 and 10 in 
the Sci-B-Vac group. In this group, mean values of 4.7 and 6.3 spots, respectively, were 
reached, whereas no response was measured in the control group as expected. One year after 
immunization IFN-γ production was still detectable in two of three tested Sci-B-Vac 
vaccinated volunteers (11 and 19 spots) whereas no response was measured in the control 
group. Taken together, only Sci-B-Vac vaccinated volunteers showed cellular immune 
responses to the PreS1 fragment of the L protein.  
 
Additionally, the S protein was used for stimulation of PBMCs (Fig. 11c). After the first and 
second immunization (week 2 and 4) IFN-γ production in T-cells was detected in a single 
volunteer immunized with Sci-B-Vac (28 spots and 43 spots). After the third and fourth 
immunization (weeks 6 and 10) IFN-γ was detectable in the Sci-B-Vac group with mean 
values of 10.6 and 18.8 spots and in the control group with mean values of 6.9 and 22.7 spots, 
respectively. One year after immunization immune responses were still detectable in two 
volunteers immunized with Sci-B-Vac (27 or 28 spots) and in one volunteer immunized with 
HBVAXPRO
®
 (60 spots). Thus, both vaccines induced similar cellular immune responses 
after stimulation with the S protein, which occurred earlier in one individual immunized with 
Sci-B-Vac.  
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Figure 11: IFN-γ production (ELISpot) after immunization with the hepatitis B vaccines Sci-
B-Vac (n =15) and HBVAXPRO
®
 (n = 15).  
The X-axis indicates time points of analysis and of immunizations (i). The Y-axis shows IFN-
γ production (spots) after stimulation with (a) L, M, and S protein; (b) L-protein fragment 
(108 aa); (c) S protein. The horizontal lines indicate mean values.  Volunteers immunized with 
[   ] Sci-B-Vac or [   ] the control vaccine. *P < 0.05, **P < 0.01, and *** P < 0.001. 
 
3.2. Immunization of potential living liver donors  
 
The aim was to show that adoptive immune transfer with the liver is feasible and can probably 
protect chronically HBV infected liver recipients from reinfection with the virus. In total 46 
potential LLD were immunized with HBV vaccines (Sci-B-Vac or HBVAXPRO
®
) to induce 
HBV specific immune responses following the short time immunization protocol described 
before. Seven donors received one booster immunization with HBVAXPRO
®
 because of 
preexisting vaccine derived HBV immunity. Humoral and cellular immune responses were 
measured in all 46 potential donors after the last immunization (Fig. 12). The number of 
immunizations differed from 1 to 5 due to the time available before transplantation or the time 
up to exclusion from donation. One donor received three booster immunizations using Sci-B-
Vac prior to donation because no anti-HBs antibodies were detectable despite of two earlier 
immunizations.  
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3.2.1. B-cell response in potential living liver donors  
 
The humoral immune response was measured in all potential donors 2-3 weeks after 
immunization (Fig. 12a). In the group of LLD who received only one immunization with Sci-
B-Vac (n = 11) four showed detectable anti-HBs antibodies of up to 189 IU/l. In LLD 
immunized twice anti-HBs antibodies were detected in four out of seven donors with up to 
825 IU/l. After three immunizations anti-HBs antibodies were present in all LLD (n = 11) 
with a peak of 2,069 IU/l. Seven of the fourfold immunized donors (n = 8) displayed anti-HBs 
titers between 44 and 9,831 IU/l. A single donor, who received five immunizations, showed 
an anti-HBs titer of 6,275 IU/l. A single booster immunization with HBVAXPRO
®
 (n = 7) 
resulted in higher anti-HBs titers of up to 61,265 IU/l. The Sci-B-Vac boosted donor 
(3 immunizations) displayed an anti-HBs titer of 22,203 IU/l. As expected, the strength of 
humoral immune responses increased with the number of vaccinations. Groups of donors who 
received booster immunizations showed higher immune responses compared to those groups 
without previous immunizations.  
 
3.2.2. T-cell response in potential liver donors   
 
Cellular immune responses were detected using proliferation assay and IFN-γ ELISpot 
(Fig. 12b and 12c). In donors (n = 11), who received one immunization with Sci-B-Vac, three 
displayed cellular immune responses in the proliferation assay (SI of up to 11.9) and one of 
them in the ELISpot (70 spots). Donors, who were immunized twice (n = 7), showed 
comparable results. Two of them showed lymphoproliferative responses (SI of up to 44.6) and 
one displayed 12 spots in the ELISpot. After three immunizations the cellular immune 
response increased. Ten out of eleven donors who received three immunizations showed 
cellular immune responses in the proliferation assay (SI of up to 22.4) and seven of them in 
the ELISpot (up to 103 spots). In fourfold immunized donors (n = 8) cellular immune 
responses were detected in five donors in the proliferation assay (SI of up to 32.5) and four 
donors displayed up to 34 spots in the ELISpot. A single donor who received five 
immunizations displayed the highest cellular immune responses. An SI of 110.2 was detected 
in the proliferation assay and 91 spots were obtained in the ELISpot. However, donors (n = 7) 
who received one booster immunization with HBVAXPRO
®
 displayed also substantial SI 
values of up to 23.4 in the proliferation assay and 75 spots in the ELISpot. The threefold 
booster vaccinated (Sci-B-Vac) donor showed lower cellular immune responses with an SI of 
3.3 and 22 spots. In summary, the magnitude of cellular immune responses also correlated 
with the number of administered vaccinations.  
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Figure 12: Humoral and cellular immune responses of 46 potential LLD after last 
immunization.  
The x-axis indicates the number of vaccinations or booster-vaccinations in 46 potential living 
liver donors.  
32 donors (   ) were excluded from transplantation due to medical or psychological reasons. 
14 donors (       ) donated a part of their liver. Values in donors who transferred their HBV 
specific immunity are depicted as hollow triangles (    ) with numbers 1-3. a) Anti-HBs titers 
in the LLD prior to transplantation or after the last immunization, b) cellular immune 
response in the proliferation assay, and c) in the IFN- ELISpot. The horizontal line indicates 
the cut-off (stimulation index of 2.5 or 10 spots, respectively). 
 
3.2.3. Immune response in LLD donating the liver  
 
In LLD humoral and cellular immune responses were measured before transplantation. 
However, only fourteen of the 46 potential LLD donated a part of their liver, while 32 were 
excluded from transplantation due to medical or psychological reasons. Three of the fourteen 
donors who donated the liver to a recipient showed anti-HBs titers > 9,000 IU/l (Fig. 12a) 
before transplantation. These three donors transferred their HBV specific immune responses 
to the recipients, while donors showing lower anti-HBs titers (n=11) did not. These three 
donors with high antibody titer after vaccination showed also cellular immune responses (Fig. 
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12b, c). Prior to the transplantation SIs of 3.3, 32.5 and 50.0 were detected in the proliferation 
assay and 52, 34 and 22 spots in the ELISpot, respectively.  
 
3.3. Characteristic of adoptive transfer of immunity to HBV  
 
Only in three of fourteen recipients the adoptive transfer was observed. In these three 
donor/recipient pairs presenting with an adoptive immune transfer the course is described 
below in detail.  
  
3.3.1. Description of immune transfer in donor/recipient pair 1  
 
In January 2006 a male donor (25 years) was evaluated for living liver donation for his HBV 
negative mother (55 years). She received the liver due to cryptogenic liver cirrhosis. The 
donor had already been immunized against HBV and showed an anti-HBs titer of 10,413 IU/l. 
After one booster immunization with HBVAXPRO
®
 an increase of the anti-HBs titer to 
57,500 IU/l was detected in the donor prior to transplantation (Fig. 13a).  
 
During the surgical treatment the patient received plasma products. Two weeks after 
transplantation an anti-HBs titer of 1,800 IU/l was detected. This could partly be due to low 
amounts of antibodies in the blood products. To demonstrate that antibodies were transferred 
with the liver and produced by B-cells of the donor we calculated the amount of anti-HBs 
which was passively transferred with blood products. During the surgical treatment she 
received a total anti-HBs amount of 380 IU/l. The decrease of these antibodies based on the 
average half-life of 21 days is calculated and visualized in Figure 13a. The amount of 
antibodies measured in the recipient, however, clearly exceeds this value and therefore, can be 
attributed to anti-HBs antibodies transferred to or produced by B-cells of the recipient. An 
anti-HBs titer of 100 IU/l in the recipient one year after transplantation suggests that anti-HBs 
was actively produced in this patient since passively transferred anti-HBs antibodies are 
unable to persist over such a long period of time. A booster immunization with 
HBVAXPRO
®
 at month 12 after transplantation induced, however, no increase of the 
antibody titer so far.  
 
In addition, the recipient showed cell proliferation after stimulation with the L-HBsAg (SI of 
4.9) at month 6 after transplantation, but at month 12 proliferation was no longer detectable. 
A booster immunization at this time point induced again an HBsAg specific cell proliferation 
38 
 
(SI of 3.1, month 13) (Fig. 13b). ELISpot results were negative in the recipient after 
transplantation (data not shown). 
 
To summarize, in this HBV naïve recipient, who received a part of the liver from an 
immunized donor, we detected the transfer of HBV specific humoral and in addition of 
cellular immune responses.  
 
Figure 13: Donor/recipient pair 1: HBV specific immunity of the donor prior to 
transplantation and the recipient pre and post transplantation.  
The X-axis indicates time points of analysis. a) The Y-axis shows anti-HBs titers in IU/l of 
the donor (        ) and the HBV negative recipient (        ). The curve indicates the half value 
time of anti-HBs derived from blood products during the transplantation. Negative (-) values 
for HBsAg and anti-HBc detection are indicated at the top. The size of the horizontal bars on 
the top indicates the amount of immunosuppressive therapy. b) The Y-axis shows the ratio 
between stimulated and unstimulated proliferation (stimulation index) of the donor and the 
HBV negative recipient using L-HBsAg as stimulus. The horizontal line indicates the cut-off 
(stimulation index of 2.5). n.t.: not tested. 
   
3.3.2. Description of immune transfer in donor/recipient pair 2  
 
In September 2006 a female HBV negative LLD (48 years old) was evaluated for living liver 
donation for her HBV negative sister (49 years old). She received the graft due to multiple 
liver abscesses. The donor was immunized against HBV in a short time immunization 
protocol using Sci-B-Vac vaccine (4 injections in 2 weeks intervals) and an anti-HBs titer of 
9,831 IU/l was observed prior to transplantation (Fig. 14a).  
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The anti-HBs titer of the recipient measured at week 2 (10 IU/l) after transplantation was 
likely due to low amounts of antibodies in blood products given during the transplantation. 
Subsequent samples of this patient were anti-HBs negative (Fig. 14a). Already one month 
after transplantation, however, the recipient showed lymphoproliferation after stimulation 
with the L-HBsAg (SI of 7.1) (Fig 14b). Again, positive results were observed at months 5 (SI 
of 3.1) and 6 (SI of 40) after transplantation. Furthermore, a transfer of cellular immune 
response was also demonstrated by IFN-γ ELISpot at month 6 (22 spots) (Fig 14c). 
 
 
 
Figure 14: Donor/recipient pair 2: HBV specific immunity of the donor prior to 
transplantation and the recipient pre and post transplantation.  
The X-axis indicates time points of analysis. a) The Y-axis shows anti-HBs titers in IU/l of 
the donor (          ) and the HBV negative recipient (          ). Negative (-) values for HBsAg 
and anti-HBc are indicated at the top. The size of the horizontal bars on the top indicates the 
amount of the immunosuppressive therapy. b) The Y-axis shows the ratio between stimulated 
and unstimulated proliferation (stimulation index) of the donor and the HBV negative 
recipient using L-HBsAg as stimulus. The horizontal line indicates the cutoff. c) The Y-axis 
shows the IFN-γ production (spots) measured by ELISpot in donor and recipient after 
incubation with the L-HBsAg. The horizontal line indicates the cut-off (10 spots). 
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Despite of a high anti-HBs titer in the donor, only cellular immune responses were 
measurable in the recipient due to the transfer of HBV specific T-cells with the liver. The 
absence of a humoral HBV specific immune response in the recipient could be explained by a 
medication with rituximab prior to transplantation and several plasmapheresis. This therapy 
was necessary to overcome blood group incompatibility of the donor and the recipient. 
Several examinations by flow cytometry have shown that no or extremely low numbers of B-
cells persisted in this recipient (data not shown).  
 
3.3.3. Description of immune transfer in donor/recipient pair 3  
 
In January 2006 a female HBV negative LLD (30 years) was evaluated for living related liver 
donation for her chronically HBV infected father (58 years). He was transplanted because of 
HBV infection related liver cirrhosis and hepatocellular carcinoma. The donor did not show a 
measurable anti-HBs titer at the time of enrolment despite previous documented vaccinations 
in September 2000 and January 2001 with 10 µg of HBVAXPRO
®
. This donor was 
immunized three times with 20 µg of Sci-B-Vac at monthly intervals. Prior to transplantation 
an anti-HBs titer of 22,200 IU/l was detected (Fig. 15a).  
 
During transplantation the recipient received blood products and HBIg (Hepatect, 286 IU/l 
daily) was administered after transplantation for a period of 21 days to prevent reinfection of 
the new liver (Fig. 15a). The anti-HBs antibodies measured on day 6 after transplantation 
(120 IU/l) could on the one hand be due to low amounts of antibodies in blood products given 
during the transplantation, or on the other hand to HBIg administration. To demonstrate that 
anti-HBs antibodies were transferred with the liver and produced by B-cells of the donor 
or/and the patient we calculated the amount of HBIg derived antibodies. According to this, the 
antibodies which were passively transferred achieved the highest concentration at day 21 with 
4,681 IU/l. At day 14 after transplantation, however, a substantial antibody titer of 
43,040 IU/l was detected in the recipient. At day 21 and at week 5 after transplantation the 
anti-HBs titer increased to 47,000 and 57,993 IU/l, respectively, and decreased at weeks 8 
(anti-HBs of 49,965 IU/l),  14 (anti-HBs of 8,397 IU/l), 19 (anti-HBs of 226 IU/l), and 26 (no 
anti-HBs detected). Therefore, the anti-HBs titer peak of 57,993 IU/l at week 5 after 
transplantation in the recipient cannot be attributed to HBIg medication. A transfer of the 
humoral immune response with the liver graft is assumed. 
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Figure 15: Donor/recipient pair 3: HBV specific immunity of the donor prior to 
transplantation and the chronically HBV infected recipient pre and post transplantation.  
The X-axis indicates time points of analysis. a) The Y-axis shows anti-HBs titers in IU/l of 
the donor (        ) and the chronically HBV infected recipient (        ). Antiviral therapy with 
lamivudine is visualized at the top with a horizontal black bar. The curve shows the level of 
anti-HBs due to HBIg medication (286 IU/l daily) considering the average half-life of the 
antibodies. Positive (+) or negative (-) results of HBsAg, anti-HBc, HBeAg, and HBV 
specific qualitative and quantitative PCR are indicated at the top. b) The Y-axis shows the 
ratio between stimulated and unstimulated proliferation (stimulation index) of the donor and 
the chronically HBV infected recipient after incubation with the L-HBsAg. The horizontal 
line indicates the cut-off (stimulation index of 2.5). n.t.: not tested. 
 
 
To show the difference in the course of anti-HBs titers between patient 3 and a chronically 
HBV infected recipient, who received the liver from a donor without HBV immunity; we 
compiled the serological results of one exemplary patient (Fig. 16). Anti-HBs titers of up to 
2,300 IU/l (week 26) could be observed in this chronically HBV infected recipient after 
transplantation. HBIg was administered to the recipient for 11 days with a daily dose of 
286 IU/l after the surgical treatment. In addition the same Hepatect dose (286 IU/l daily) was 
administered for 10 days at weeks 8 and 9 as well as at weeks 19 and 20 after transplantation. 
The half life time of Hepatect derived antibodies was calculated and a peak of 2,988 IU/l 
(week 8) is visualized in Figure 15.  
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Figure 16: Humoral immune response of a chronically HBV infected recipient who received 
the liver from a donor without HBV immunity.  
The X-axis indicates time points of analysis. Positive (+) or negative (-) results of HBsAg, 
anti-HBc, HBeAg, and HBV specific qualitative PCR are indicated at the top. The Y-axis 
shows anti-HBs titers in IU/l of the donor and the chronically HBV infected recipient (         ). 
The administration of HBIg (Hepatect) for 11 days after transplantation and for 10 days at 
week 8 and 9 as well as at week 19 and 20 (286 IU/l daily) are visualized as grey bars. Before 
and after transplantation the recipient received lamivudine therapy as indicated with a black 
bar. Further, the reduction of immunosuppressive therapy is shown with the size of the 
horizontal bar. 
 
The amount of anti-HBs, which was measured in this chronically HBV infected patient can 
usually be observed in recipients due to HBIg medication (data not shown). The anti-HBs 
antibodies in recipient 3 were more than 1 log higher than in the control patient and, therefore, 
not solely due to HBIg administration. 
 
To show that the vaccine which was used for the immunization of the donor is suitable to 
overcome the chronic infection in the recipient, we examined the HBV genotype and subtype 
persisting in the recipient. The vaccine, Sci-B-Vac, which was used for the immunization of 
the donor, is based on A2/HBsAg genotype and subtype adw2. The recipient was infected 
with an HBV isolate of the same genotype and subtype (A2/HBsAg adw2). Therefore, the 
vaccine was suitable to overcome the infection in the recipient. The specificity of anti-HBs 
antibodies in the recipient was tested. These antibodies were neutralized by all three different 
HBsAg subtypes (adw, adr, and ayw) indicating that the major portion of anti-HBs was 
directed to the a-determinant (data not shown). Thus, anti-HBs antibodies present in the 
patient after transplantation were likely to possess the ability to neutralize HBV viral 
43 
 
particles. A part of the circulating anti-HBs antibodies, however, derived from HBIg 
administration.  
 
In addition to the humoral immune response to HBsAg, cellular immune responses in 
donor/recipient pair 3 were measured in proliferation assays. Prior to the transplantation an L-
HBsAg protein specific immune response (SI of 3.3) was detected in the donor and no 
immune response in the recipient (Fig. 15b). At week 26 after transplantation the recipient 
developed an L-HBsAg protein specific cellular immune response with an SI of 3.1. No 
immune responses could be detected in the recipient before and after transplantation by 
ELISpot (data not shown).  
 
We measured HBsAg, HBeAg and HBV DNA one week before and at several time points 
after the transplantation in patient 3. Prior to transplantation these three parameters were 
positive. At day 4 after transplantation a low level of HBV DNA was detected despite the 
presence of anti-HBs. Therefore, antiviral therapy with lamivudine was started on day 5 after 
transplantation. Afterwards, HBV DNA was no longer detectable. From week 19 onwards 
low levels of HBV DNA (< 357 IU/ml) and HBsAg were detected again in the serum. 
However, no HBeAg could be measured. Unfortunately, further observation was not possible, 
because the patient died at week 28 after transplantation due to perforating lung metastases. 
 
3.3.4. Summary of the adoptive immune transfer 
 
The follow up of three patients indicates that adoptive immune transfer with the liver is 
possible in humans. However, as shown in donor/recipient pair one and three, high titer of 
anti-HBs (> 9,000 IU/l) is required to transfer the humoral immune response from donor to 
the recipient. In addition, we were able to show that cellular immune response can also be 
transferred from donor to HBV naïve recipient (donor/recipient pair 1 and 2). In addition, 
transfer of HBV specific immunity to a chronically infected recipient is possible 
(donor/recipient pair 3). However, additional patient pairs have to be investigated to 
determine whether the adoptive immune transfer can protect chronically HBV infected 
patients from reinfection with the virus. In addition immunization of chronically infected 
patients after adoptive immune transfer should be performed to boost transferred HBV 
specific immune response.        
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3.4.  Characterization of WHV virus like particles (VLP)  
 
In the first two parts of the studies we increasingly investigated adoptive transfer of immunity 
by liver transplantation. These experiments showed that adoptive immune transfer is only 
possible after induction of high titers of HBV specific antibodies in donors. These 
experiments encouraged us to examine a new type of hepadnaviral vaccine to enhance the 
immune response to PreS1. So far the most HBV vaccines do not contain PreS1 region of the 
HBV L protein. In several studies a PreS1 peptide was demonstrated to interact with the 
receptor of hepatocytes. PreS1 peptide fused to the hepadnaviral core protein virus-like 
particles (VLPs) represents an interesting approach to improve hepatitis B vaccines. Thereby, 
a broader range of virus neutralizing protective antibodies could be induced resembling the 
repertoire of protective antibodies acquired during natural infection. Such vaccine inducing 
both the humoral and cellular immune response may qualify for prophylactic immunization as 
well as for therapeutic vaccination of chronic HBV carriers.  
 
As a preclinical model we used woodchuck (Marmota monax) which can be infected with the 
woodchuck hepatitis virus (WHV). WHV is a member of the family Hepadnaviridae and is 
closely related to HBV (Lu et al., 2001). The generated VLPs are composed of WHV core 
proteins with insertion of WHV PreS1-derived peptides. In the future the WHV model will be 
used to proof if generated particles are suitable for therapeutic and/or prophylactic 
vaccination.  
 
3.4.1. Prediction of the major immunodominant region (MIR) of WHV core.  
 
The structure of HBV core particles was already published in 1994 (Crowther et al., 1994). 
One of the most interesting sites for insertion of epitopes into HBV core protein is the major 
immunodominant region (MIR). This region is located in the loop region aa 74-89. The MIR 
of WHV core protein was, unfortunately, not defined during the performance of this project 
but the sequence of WHV core protein was already known. Due to a high homology between 
HBV and WHV core protein of about 80 % we used the known structure of HBV core to 
predict the structure of WHV core. Therefore we used the 3D-JIGSAW software (see 
Methods section 2.3.12). This application is able to build three-dimensional maps based on 
homologies of highly resolved structures. Due to findings based on this technology we 
defined the spike of WHV core truncated protein near to the region between aa 74-78 
(Fig. 17). 
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Figure 17: Predicted 3D structure of WHV core protein.  
a) Structure of truncated WHV core protein (149 aa residues). b) Major immunodominant 
region (MIR) of truncated WHV core protein with amino acid sequence (3 letter code) and the 
position within the expected loop region (Bates et al., 2001). 
 
3.4.2. Construction of plasmids containing WHcAg aa 1-149 with PreS1 Pep1-Pep6 inserts.  
 
One aim of these experiments was to insert the PreS1-fragment, which induce neutralizing 
antibodies, into a WHV core VLP. For HBV the PreS1 region, which induces neutralizing 
antibodies, is known. Unfortunately, this region has not yet been defined for WHV PreS1. 
The homology of HBV PreS1 and WHV PreS1 protein- sequence is unfortunately very low; 
therefore we were not able to predict the region, which is necessary to binde to the receptor of 
hepatocytes. Therefore, we decided to create six VLP-constructs with partial sequences of 
WHV PreS1 starting from the n-terminus and in the sum bearing the whole WHV PreS1 
fragment. Six overlapping PreS1 fragments (for protein- and DNA-sequence see appendix 
7.2), corresponding to the whole PreS1 part of the L protein, were inserted into the major 
immunodominant region (MIR) of the WHcAg.  
The PQE60 plasmid containing WHcAg region including Bsp119 restriction site in the MIR 
of WHcAg was kindly provided by Dr. Menji Lu. The PCR products of the six PreS1 peptides 
(Pep1-Pep6) were amplified using PCR primers including Bsp119 restriction sites. Plasmid 
and PCR-products were digested by Bsp119 enzyme and ligated using T4 DNA ligase (see 
Methods 2.3.13). All generated constructs were verified by DNA sequencing (for sequence 
see section 7.1 of the appendix). The schematic illustration of the constructs was shown in 
figure 18.  
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Figure 18: WHV PreS1 peptides and their position after insertion into the truncated WHV 
core protein.  
a) Schematic illustration of WHV PreS1 protein and the position of PreS1 peptides (Pep1-
Pep6). b) Schematic illustration of wild type core protein and WHV core constructs with 
Pep1-Pep6 insertions between aa 78 and aa 79. Used protein names are listed on the left. 
 
 
 
3.4.3. Purification of capsids  
 
Six constructs WHcPep1-WHcPep6 that encoded the truncated WHcAg with PreS1 fragments 
as inserts (Pep1-Pep6) were used to test their ability of protein expression, solubility, 
formation and stability of VLPs. The wild type truncated WHcAg construct Q60WHc has 
been used as a control. The constructs were transformed into E. coli strain BL21. After 
approximately 3 hours expression in growth medium at 37°C, bacteria were lysed and protein 
expression and solubility of the proteins were examined by PAGE-electrophoresis. The 
distribution of soluble and insoluble proteins were examined by Western blot using HBV 
antibody anti-HBc mAb 14E11 which is cross-reactive to WHV core and was kindly provided 
by Prof. Dr. Paul Pumpens (Fig. 19).   
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Figure 19: Examination of the solubility of expressed proteins.  
The insoluble (1) and the soluble (2) part of the expressed proteins were detected by Western 
Blot. a) Q60WHc, b) WHcPep1, c) WHcPep2, d) WHcPep3, e) WHcPep4, f) WHcPep5 and 
g) WHcPep6 
  
The wild type core protein (Q60WHc) was expressed and a large part of the protein was 
soluble as shown in the Western blot (Fig. 19a). The electromicroscopic investigation 
confirmed that Q60WHc formed VLPs (Fig. 20a).  
The experiments with chimeric proteins (expressed from constructs: WHcPep1-WHcPep6) 
demonstrated different particle formation (Fig. 20b-g and table 9).  
 
Table 9: Conditions, methods and results of VLP production 
 
Three methods, aluminium oxide, lysozyme or sonication, respectively, were used for lysis of 
the bacteria. For each construct we selected the lysis method, which provided the most 
efficient transfer of the chimeric protein into the soluble part. In some cases, 1.5 M urea was 
added to dissolve particles. Higher urea concentrations disrupted the formation of VLPs. All 
expressed proteins formed VLPs as demonstrated in electro microscopic figure 20.  
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Figure 20: Electron microscopic pictures of the VLPs.  
VLPs formed after purification of a) Q60WHc, b) WHcPep1 protein, d) WHcPep3 protein, e) 
WHcPep4 protein and g) WHcPep6 protein (in 50% glycerol). Particles are highlighted by an 
arrow. c) WHcPep2 and f) WHcPep5 were not suitable for purification. Particles were 
visualized after lysis.  
 
After purification WHcPep1 degraded very fast and particles could not be used for 
immunization studies. Most VLPs expressed from construct WHcPep2 were insoluble and to 
low for purification. The stability after purification of VLPs expressed from WHcPep5 was 
very low; therefore no particles for immunization studies could be used. Nevertheless, VLPs 
expressed from three constructs (WHcPep3, WHcPep4 and WHcPep6) were purified and 
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could be used for immunization of mice. For the lysis we used sonication in case of WHcPep3 
and WHcPep6. Aluminium oxide was used as lysis method for bacteria expressing WHcPep4 
(see section Methods 2.3.14). 
 
3.4.4. Production of the WHV PreS1-GST protein  
 
To measure antibodies to WHV PreS1 we established an ELISA. Therefore the whole WHV 
PreS1 fragment fused to GST was generated to be used as an antigen. To generate PreS1 (aa 
1-149)-GST protein, the preS1 gene was inserted into the pDest24 vector using GATEWAY 
technology as already described (see Methods 2.3.16 and Fig. 21).  
After cloning, the preS1-gst containing section of the vector was checked by sequence 
analysis. The plasmid that encoded the estimated sequence (plasmid PreS1-GST) was used for 
transformation of E. coli strain BL21. After growing of the transformed E. coli and the 
induction of the protein expression, the bacteria cells were lysed and the expressed protein 
was purified by the GST-sepharose column chromatography (see Methods 2.3.17). The 
protein was visualized using GST specific antibodies in Western blot. The undigested protein 
(46 kDa) was purified again using SDS-gel purification, as degraded products were identified 
(Fig. 20a). The purified protein (Fig. 21b) with a concentration of 0.15 mg/ml was stored at 
− 20°C. For ELISA, wells were coated with a concentration of 150 ng PreS1-GST per well.  
 
 
 
  
 
 
 
 
 
Figure 21: Purification of the PreS1-GST protein.  
(a) SDS-gel electrophoresis after GST-sepharose column chromatography (coomassie 
staining). The left lane shows the protein ladder. The 46 kDa band on the right lane indicates 
the PreS1-GST protein. The remaining bands show degraded protein. (b) GST specific 
Western blot (using anti-GST antibody see 2.3.17) after SDS-gel purification. The 46 kDa 
band indicates the PreS1-GST protein. 
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3.4.5. Immunization of BALB/c mice  
 
The aim of our experiments was to induce stronger and faster humoral immune response as 
compared to immunization with peptides. In subsequent experiments we immunized 16 
BALB/c mice with VLP constructs WHcPep3 (aa 48-80) (n = 4), WHcPep4 (aa 70-101) 
(n = 4), WHcPep6 (aa 121-149) (n = 4) and with n-terminal PreS1 fragment aa 1-81 (n = 4). 
In two-week intervals we determined humoral immune responses to demonstrate that the 
purified VLPs are suitable to induce better immune response compared to immunization with 
the PreS1 fragment aa 1-81. The humoral immune response was measured using PreS1-GST 
(aa 398) specific ELISA before and after each immunization. We examined the humoral 
immune response (PreS1-GST specific ELISA) prior to immunization and at week 2, 4 and 7 
after beginning of immunizations (Fig. 22).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: WHV PreS1-specific humoral immune response in WHcPep3, WHcPep4, 
WHcPep6 and Pep1-vaccinated mice. 
BALB/c mice were immunized three times with construct WHcPep3, or WHcPep4, or 
WHcPep6 or peptide Pep1, respectively. After each immunization WHV PreS1-specific 
antibodies were determined. The mean value for each group is indicated by a bar. 
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Antibodies to PreS1 were undetectable prior to immunization (week 0) in all groups. After the 
first immunization all groups of mice immunized with VLPs showed PreS1 specific humoral 
immune response; whereas mice immunized with the PreS1 fragment aa 1-81 showed no 
immune response at this time point. This difference was statistically significant in case of 
WHcPep4 with P value of < 0.05. After second immunization two mice immunized with 
PreS1 fragment showed humoral immune response. In comparison all mice immunized with 
particles developed humoral immune response. The difference was also here statistically 
significant in case of WHcPep4. These results indicate that the produced particles induce 
earlier humoral immune response as compared to PreS1 fragment aa 1-81. After the last 
immunization all groups of mice developed humoral immune response to PreS1-GST. The 
neutralizing capacity of induced antibodies should still be tested.  
 
In summary, we could show that WHV core VLPs produce a fast immune response already 
two weeks after the first immunization. These particles can now be used for immunization of 
woodchucks. Probably this vaccine can also be used for chronically infected woodchucks to 
check its ability for therapeutic vaccination.  
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4. Discussion  
 
Liver transplantation is mostly the ultimate therapeutic option for patients with liver failure 
due to liver cirrhosis or hepatocellular carcinoma caused by HBV-, HCV-infection, 
autoimmune hepatitis or alcohol abuse. The lack of suitable organs led to an increased 
number of partial liver transplantations from living liver donors (LLD) (Broelsch et al., 2003). 
The HBV reinfection, however, is still a problem despite of a combined therapy with 
lamivudine and hepatitis B immunoglobulin (Lai et al., 1998; Tillmann et al., 1999). Adoptive 
transfer of HBV immunity with the liver of vaccinated donors could be a new approach to 
prevent reinfection in the recipients. In the last few decades several groups described 
detection of microchimerism after liver transplantation and a lymphocyte transfer within the 
transplanted liver (Schlitt et al., 1993). In countries with a high prevalence of HBV, the 
chance to transplant a liver from an immune donor is high and subsequent adoptive immune 
transfer is possible (Lo et al., 2003; Luo et al., 2007). In low prevalence areas like Europe, 
however, immune donors are rare. Therefore vaccination of LLD for adoptive immune 
transfer could be an alternative.  
 
4.1. Short time immunization 
 
The active HBV immunization of the donors for adoptive immune transfer with the liver graft 
has never been performed in humans. To date it is not clear to which degree HBV specific 
immunity, induced by immunization, can be transferred by liver transplantation. However, the 
adoptive transfer of humoral HBV specific immunity by liver transplantation has already been 
analyzed in the rat model (Dahmen et al., 2003a). After immunization, the rats displayed 
mean anti-HBs titers of approximately 100,000 IU/l. The corresponding non-immunized 
recipients showed anti-HBs titers of approximately 100 IU/l at week 1 after liver 
transplantation. These experiments indicate that only a small proportion of antibody-
producing lymphocytes can be transferred to the recipient.  
 
Because of the small amount of HBV specific B- and T-cells which can be transferred with 
the liver we expect that it is necessary to induce strong immune responses in the donors. 
However, the time in which to achieve this immune response is rather short (1-2 months). 
Therefore, we established a short time immunization protocol using Sci-B-Vac, a recently 
developed S, M and L protein containing HBV vaccine (Schumann et al., 2007). But the 
applicability of short time immunization protocols is not limited to liver donation settings. 
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Adolescents who are non- or low-responders after vaccination in a standard vaccination 
schedule (Wallace et al., 2004) and travelers who need HBV immunity within a short time 
would also profit from this vaccination scheme.  
 
Sci-B-Vac has already been shown to induce stronger humoral immune responses compared 
to vaccines containing only the S protein. In the conventional HBV vaccination protocol 
(immunization at month 0, 1, and 6) with a vaccine dose of 10 µg Hourvitz et al. observed 
anti-HBs titers of 13,483 IU/l (GMT) after the third immunization with Sci-B-Vac at month 7 
(Hourvitz et al., 1996). However, at month 12 the GMT decreased to 3,273 IU/l. In a short 
time immunization protocol (immunization at weeks 0, 2, 4, and 6) and a 2-fold higher 
vaccine dose (20 µg) we induced an anti-HBs titer of 843 IU/l (GMT) within 2 months.  
 
Several placebo-controlled, double blind randomized trials showed safety of S containing 
vaccines by preventing hepatitis B in high risk groups (Szmuness et al., 1981; Coutinho et al., 
1983). In general prevention from HBV infection is mostly achieved with anti-HBs titers 
higher than 10 IU/l. Our short time immunization protocol induced higher antibody titers 
which are relevant for the immediate protection against the virus.  
 
Cellular immune response to the surface- and core-proteins in chronically infected patients is 
low or absent as compared to individuals resolving the infection or vaccinated individuals, 
respectively. Immunization of chronically infected patients with the S protein 
(HBVAXPRO
®
) cannot induce cellular immune responses (unpublished data, M. Fiedler and 
M. Lindemann). Cellular immune response to the core protein has already been shown to 
protect against infection in the woodchuck model (Roos et al., 1989; Menne et al., 1997; Lu et 
al., 1999). However, therapeutic vaccination with core protein in preclinical studies in 
chronically infected woodchucks was not efficient and vaccines containing the core protein 
are still not available for humans. Therefore, we used the highly immunogenic S, M and L 
protein containing vaccine as an alternative. Possibly the adoptive transfer of both humoral 
and cellular immune responses to the S, M and L proteins could be sufficient to control 
reinfection with the virus. 
 
Similar to other available L, M and S protein-containing vaccines (Jones et al., 1998; 
McDermott et al., 1998; Jones et al., 1999) we could show cellular immune responses after 
vaccination with Sci-B-Vac. In addition to the conventionally used proliferation assay we 
measured the IFN-γ production by ELISpot. Thereby, the cellular immune response was 
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detected earlier (after the first vaccination) compared to the proliferation assay. In this assay 
proliferation of CD4 T-cells was detected after vaccination. Thus, IFN-γ ELISpot seems to be 
more sensitive for the early detection of the cellular immune response after vaccination with 
Sci-B-Vac. 
 
To verify that the cellular immune response is also directed against PreS1 we decided to use a 
fragment of the L protein (108 aa) for stimulation. The Sci-B-Vac immunized volunteers 
showed cellular immune responses to that protein while the control group immunized with the 
S protein as expected did not. The L protein contains additional B- and T-cell epitopes and 
may induces neutralizing antibodies. The data on the stimulation with the S protein were 
comparable in the Sci-B-Vac and in the control group. Both vaccines contained this HBV 
protein.  
 
4.2.  Adoptive immune transfer 
 
In the first part of this study a short time immunization protocol was established in order to 
induce high immune responses in LLD before transplantation and thereby to protect 
chronically HBV infected patients from reinfection of the liver graft by adoptive immune 
transfer. We have shown that vaccination with Sci-B-Vac induces strong immune responses 
in a short time immunization protocol (Schumann et al., 2007). Those immune responses, 
however, were lower in LLD compared to healthy volunteers. The reason for the reduced 
immune response could be psychological stress during the evaluation period of LLD. Several 
studies have already shown that mental pressure suppresses immune responses to HBV 
vaccines (Burns et al., 2002). In this part of the study, however, HBV specific adoptive 
transfer of humoral, and for the first time, of cellular immune responses with the human liver 
was demonstrated (Schumann et al., 2009). 14 of 46 immunized donors were accepted for 
donation. The transfer of the humoral and/or cellular immune responses was detected in 3 of 
14 recipients. Two recipients were HBV naïve (recipients 1 and 2) and one was chronically 
HBV infected (recipient 3). In the corresponding donors anti-HBs titers > 9,000 IU/l were 
measured. Probably, due to the induction of intermediate anti-HBs titers 100 - 1,000 IU/l in 
10/14 donors the transfer of immune responses to their corresponding recipients was not 
observed. The transfer of antibodies seems to depend on the level of the HBV specific 
humoral immunity in the donor prior to transplantation. Luo et al. have shown that 
particularly the humoral immune response (anti-HBs titers >1,000 IU/l) in the donor is 
essential for the adoptive immune transfer (Luo et al., 2007). In this study donors were not 
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vaccinated but had previous HBV infection. In our study, however, one donor with a high 
anti-HBs titer of 6,000 IU/l and additionally the highest cellular immune response did not 
transfer HBV specific immunity to the corresponding recipient. Possibly, immunity after 
infection is associated with a higher amount of HBV specific T-cells in the liver compared to 
that in livers of immunized donors. Therefore, immunized donors probably require higher 
member of B-cells to transfer their immunity than donors after resolved HBV infection. A 
calculation of minimal anti-HBs titer that is required for adoptive immune transfer from 
immunized donors is difficult. 
 
In the chronically HBV infected recipient 3 an anti-HBs titer of 58,000 IU/l was measured 
after transplantation. Only about 4,700 IU/l of anti-HBs were calculated to be due to HBIg 
administration in recipient 3. In week 19 after transplantation HBV-DNA reappeared and 
anti-HBs was no longer measurable. This possibly indicates that adoptive transfer of HBV 
specific immunity was not sufficient in this patient to prevent graft reinfection. The state of 
health of this chronically HBV infected recipient, however, rapidly worsened due to the tumor 
at this time point. The patient died two months later. Probably, the development of a tumor 
impaired the function of the immune system. This aspect needs to be examined in a larger 
cohort of patients. 
 
In order to clarify, if cells of the immunized donors or the recipients induced HBV specific 
immune responses we investigated the presence of microchimerism. In donor/recipient pair 1, 
cells of the male donor were not measurable by Y chromosome-specific PCR in the PBMCs 
of the female recipient one year after transplantation (data not shown). In other studies, it was 
shown that the frequency of transferred donor cells is mostly below 1% one month after 
transplantation and even lower thereafter (Jonsson et al., 1997; Ueda et al., 1997). Therefore 
we were not able to detect donors DNA by PCR. Microchimerism, however, still does not 
clarify the question, if the cells of the donor or of the recipient induce HBV specific B- and/or 
T-cell immune responses. Therefore, it would be necessary to evaluate a method to detect 
donor specific and simultaneously HBV specific cells in the recipient. Flow cytometry 
analysis allows the detection of donor/recipient specific HLA markers and simultaneously 
HBV specific cells. So far, however, we were not able to detect HBV specific B- and/or T-
cells in the recipient after transplantation using flow cytometry analysis. On the one hand this 
could be due to the low frequency of HBV specific cells. Furthermore, it has been shown that 
detection of antigen specific T-cells by flow cytometry analysis is less sensitive than by 
ELISpot assay (Tassignon et al., 2005). Taken together, the evaluation of a protocol, which 
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can detect simultaneously donor specific and HBV specific cells, is not an easy task but an 
important goal to prove adoptive immune transfer by solid organ transplantation.  
 
In conclusion, HBV specific adoptive immune transfer to transplanted patient due to chronic 
HBV infection in the setting of living liver transplantation is feasible. Our results clearly 
indicate that only high titers of anti-HBs in the donor result in immune transfer. It could be 
beneficial to extend the time for donor vaccination if possible. Hopefully in the future most 
possible donors are already immune due to vaccination programs for children in many 
countries. Further, a promising way to overcome the reinfection of the new graft in 
chronically HBV infected liver recipients could be the combination of adoptive immune 
transfer followed by booster immunizations. Either vaccines with highly immunogenic 
adjuvants like MPL/QS21 (Bienzle et al., 2003; Bauer et al., 2007) or third generation 
vaccines should be used (Lo et al., 2007). Further, the use of adoptive immune transfer could 
especially be useful for patients in countries where the medication with anti-HBs antibodies 
or/and improved vaccines is not available.  
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4.3.  Characterization of WHV VLP 
 
The worldwide prevalence of HBV clearly emphasizes need of prophylactic vaccination and 
improved therapy in patients with chronic HBV infection. Vaccines against HBV are 
available since 1980s. Protective immune response, however, can be reached in about 90 – 
95% of all vaccine recipients. Therefore one aim of this thesis was to characterize the vaccine 
improvement by HBV PreS1 protein. One important function of PreS1 protein is binding to 
the NTCP receptor of cells to enable the entry of the virus into host which is mainly the 
hepatocyte. The n-terminal part of PreS1 was considered as the receptor binding site (Meier et 
al., 2013) and recently the receptor was identified (Yan et al., 2012; Zhong et al., 2013). 
Hepadnaviral core protein offers the ability to act either as T-cell and B-cell antigen. Thereby 
a vigorous T-cell immune responses and various repertoire of antibodies can be induced.  
Therefore PreS1 in combination with hepadnaviral core protein virus-like particles (VLP) 
represent an interesting approach for prophylactic hepatitis B vaccine. Thereby, T-cell 
dependent immune responses and a broader range of neutralizing antibodies could be induced 
resembling the repertoire of antibodies acquired during natural infection (Neurath et al., 
1987). 
Purification of HBV PreS1-core particles in E. coli was successful performed by two groups 
(Kazaks et al., 2004; Malik et al., 2012). In addition the ability to induce antibodies was 
approved in mice. Unfortunately, mouse is not the natural host of HBV and can therefore not 
be infected with the virus. Thus, the protecting proprieties of HBV PreS1-core particles as 
therapeutic and/or prophylactic vaccine could not be tested in vivo. In vitro, however, Tupaia 
belangeri hepatocytes which can be infected with HBV were used for testing of neutralizing 
capacity of these antibodies (Glebe et al., 2003). Tupaia belangeri, however is not the natural 
host of hepadnaviruses and could not be used for protection studies in vivo. 
 
As a preclinical in vivo model we used therefore the woodchuck (Marmota monax) which can 
be infected with the woodchuck hepatitis virus (WHV). In contrast to HBV, the PreS1 binding 
side of WHV and the receptor in the host was not identified so far. Therefore overlapping 
peptides (Pep1-Pep6) bearing the whole PreS1 sequence were used to create six VLPs. The 
PreS1 region, which induces neutralizing antibodies in the woodchuck model, should be 
identified. Meanwhile protection against WHV using the WHV PreS1 fragment aa 1-81 as 
antigen was successfully performed (Schumann and Brovko et al., unpublished data). This 
finding is in accordance with HBV PreS1 in vitro studies performed in the past (Ryu et al., 
1997; Hong et al., 2004; Glebe et al., 2005; Glebe, 2006). Further, WHV core antigen alone 
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has been shown to protect woodchucks from WHV infection (Menne et al., 1997). Acute 
WHV infection in woodchucks can furthermore similar to HBV change to a chronic disease. 
This model is therefore suitable to examine not only prophylactic but as well therapeutic 
ability of PreS1-core particles.  
 
In this study WHV core particles containing WHV PreS1 inserts were created similar to 
HBV particles constructed by Borisova (Borisova et al., 1990). The major immunodominant 
region (MIR) of WHV core protein was identified using a prediction system based on the 
known HBV core protein structure (Wynne et al., 1999; Tan et al., 2007). Based on this 
prediction, PreS1 peptides were inserted between aa 78 and 79 of the WHV core protein. 
Meanwhile, Billaud et al. have shown that WHcAg appears to tolerate insertions of foreign 
epitopes at a greater length and different positions than HBV core protein (Billaud et al., 
2005a; Billaud et al., 2005b). They predicted aa 78/79 of the WHV core as a tolerant 
insertion site for insertion of foreign epitopes. These findings correlate with our data, since 
analysis of the bacterial lysates demonstrated that all six chimeric WHV core-PreS1 proteins 
were assembled into VLP (Fig 20). Unfortunately we were not able to purify all six PreS1-
core particles. However, the PreS1-core particles WHcPep3, WHcPep4 and WHcPep6 were 
purified. Immunization of mice with chimeric particles purified in this study (WHcPep3, 
WHcPep4, WHcPep6) induced high antibody tiers which were better than after immunization 
with the n-terminal PreS1-fragment aa 1-81. Meantime Brovko et al. purified core particles 
using a Split-core system based on HBV core protein (Walker et al., 2011) and purified 
particles containing the WHV PreS1 region aa 22−38 (Brovko, 2012). Further a WHV PreS1 
B-cell epitope (aa 22-25) was identified. Similar to our results, however, split-core-particles 
based on WHV core protein bearing the PreS1 region 22-38 could not be purified.  
 
 
Finally, particles created in this study can be used in the woodchuck model to confirm the 
protection ability and safety of this vaccine for application of HBV VLP in humans. 
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4.4.  Future Prospects 
 
VLPs developed in this thesis induce core specific T- and B-cell immune response against 
Hepadnaviral infection and simultaneously improve immunogenicity of PreS1 by elevating 
the titer of PreS1-specific antibodies. Probably, a PreS1-insert smaller in length can improve 
the solubility and particularly purification ability of the chimeric WHV PreS1-core VLPs. 
Meantime a WHV PreS1 B-cell epitope aa 22-25 was identified (Brovko, 2012). Chimeric 
WHV core particles containing this epitope should be developed to examine their sufficiency 
in therapeutic vaccination of individuals suffering from chronic hepadnaviral infection. 
Chimeric particles created in this study, however, can be used to confirm its safety and 
protection ability in vivo using woodchucks as animal model. 
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6. Summary 
 
Liver transplantation is often the ultimate option of therapy for chronically hepatitis B virus 
(HBV) infected patients. Prevention of reinfection by HBIg is long-lasting and cost-intensive. 
Adoptive transfer of HBV immunity after transplantation of the liver from an immune living 
liver donor (LLD) could be a new approach to prevent reinfection in the recipients.  
A short time immunization protocol (four injections in 2 weeks intervals) was established to 
achieve HBV immunity in LLD within 2 months. Using this protocol, the humoral and cellular 
immune response of Sci-B-Vac, a recombinant vaccine that contains HBV L, M and S surface 
proteins was compared with a standard HBV vaccine (HBVAXPRO
®
) that contains only the S 
surface protein. The humoral immune response could already be detected after the first 
immunization in nine out of fifteen Sci-B-Vac vaccinated individuals while it was only 
observed in one out of fifteen volunteers of the group immunized with HBVAXPRO
®
. Anti-
HBs titers were significantly higher in Sci-B-Vac volunteers (P < 0.01) following all four 
vaccinations. HBV-specific T-cell immune response was significantly higher in Sci-B-Vac 
volunteers (P < 0.001) after the third vaccination. Proliferative response was also significantly 
(P < 0.01) higher in the Sci-B-Vac group after second to fourth vaccination.  
With this good experience, Sci-B-Vac was subsequently used for vaccination of forty-six 
potential LLD using the short time immunization protocol as described above. Humoral and 
cellular immune responses were examined in donors after immunization and in recipients before 
and after transplantation. Anti-HBs-titers of up to 50,000 IU/l were detected in LLD. Fourteen 
patients received livers from these immunized donors. We detected humoral immunity in one 
HBV-naïve recipient and in one chronically HBV-infected recipient. A transfer of cellular 
immunity (SI > 3) was seen in three recipients. These three patients received livers from donors 
with high anti-HBs-titers of more than 9,000 IU/l. Cellular immunity was also detected in the 
corresponding donors (SI > 3 and spots > 22). Our study demonstrates that HBV-specific 
humoral and cellular immunity can be transferred by liver transplantation after vaccination of 
the donors. The transfer of B- and T-cell immunity in transplanted patients correlates with the 
magnitude of immune responses in the donor.  
Further, using the woodchuck model we successfully expressed six chimeric PreS1-core 
particles (WHcPep1, WHcPep2, WHcPep3, WHcPep4, WHcPep5, WHcPep6) in E. coli. We 
successfully purified three out of six constructs (WHcPep3, WHcPep4, WHcPep6). 
Immunization of mice with chimeric particles purified in this study induced a better immune 
response compared to immunization with an n-terminal PreS1-fragment aa 1-81. Already, 
after the first immunization all groups of mice immunized with virus like particles (VLPs) 
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showed PreS1 specific humoral immune response; whereas mice immunized with the PreS1 
fragment aa 1-81 showed no immune response at this time point. Particles created in this 
study can be used in the future in woodchucks to confirm the protection ability and safety of 
this vaccine for application of HBV VLPs in humans. 
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7. Zusammenfassung 
 
Die Lebertransplantation ist die letzte Therapiemöglichkeit für chronisch Hepatitis-B-Virus 
(HBV) infizierte Patienten. Die Prävention einer HBV-Reinfektion durch Immunglobuline ist 
langwierig und teuer. Eine mögliche Alternative die Reinfektion zu verhindern könnte der 
adoptive Transfer von HBV-Immunität durch Lebertransplantation nach Impfung eines Leber-
Lebendspenders sein. 
Im ersten Teil dieser Arbeit wurde ein Kurzzeit-Immunisierungsprotokoll (vier Impfungen in 2- 
wöchigen Abständen) etabliert, um eine HBV-spezifische Immunantwort innerhalb von 
2 Monaten zu induzieren. Bei diesem Immunisierungs-Schema wurde die humorale und 
zelluläre Immunantwort nach Impfung mit Sci-B-Vac, einem rekombinanten Impfstoff, der aus 
den Oberflächenproteinen L, M und S besteht, verglichen mit dem Standardimpfstoff, der nur 
das S Protein besitzt (HBVAXPRO
®
). Bei neun von fünfzehn Impflingen der Sci-B-Vac-
Gruppe konnte bereits zwei Wochen nach der ersten Impfung eine humorale Immunantwort 
detektiert werden. Bei den HBVAXPRO
®
- Impflingen konnte zu diesem Zeitpunkt bei nur 
einem von 15 Probanden eine humorale Immunantwort nachgewiesen werden. Die anti-HBs 
Titer waren in der Sci-B-Vac-Gruppe nach der ersten bis vierten Impfung signifikant höher 
(P < 0.01). Die HBV-spezifische T-Zellproliferation war in der Sci-B-Vac-Gruppe nach der 
zweiten, dritten und vierten Impfung signifikant höher (P < 0.01). 
Aufgrund der guten Ergebnisse mit dem Impfstoff Sci-B-Vac wurden 46 potentielle Leber-
Lebendspender nach dem oben beschriebenen Kurzzeit-Immunisierungsprotokoll geimpft. Die 
humorale und zelluläre Immunantwort wurde bei den Spendern nach Impfung und bei den 
Empfängern vor und nach Transplantation gemessen. Anti-HBs Titer von bis zu 50000 IU/l 
wurden bei den Spendern nach Impfung detektiert. Vierzehn Empfänger haben ein Teil der  
Leber der geimpften Leber-Lebendspender erhalten. Eine humorale Immunantwort wurde nach 
Transplantation bei einem vorher HBV-naiven Empfänger und bei einem chronisch HBV-
infizierten Empfänger nachgewiesen. Ein Transfer der zellulären Immunität (SI > 3) wurde bei 
drei Empfängern detektiert. Diese drei Patienten hatten Lebern von Spendern erhalten, deren 
anti-HBs Titer höher als 9000 IU/l waren. Die zelluläre Immunantwort war bei den 
korrespondierenden drei Spendern ebenfalls kräftig [(SI > 3 und HBV-spezifische Interferon- 
Spots > 22 (ELISpot)]. Diese Studie zeigt, dass die humorale und zelluläre Immunantwort nach 
Impfung der Spender mit der Leber übertragen werden kann. Der Transfer von B- und T-Zell-
Immunität korreliert dabei mit der Stärke der Immunantwort des Spenders. 
Weiterhin wurden im Murmeltier-Model sechs Virus-ähnliche-Partikel (VLP) konstruiert. Diese 
Partikel beinhalten neben dem Core-Protein auch Peptide aus der PreS1-Sequenz des 
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Woodchuck-Hepatitis-Virus. Drei von sechs VLP (WHcPep3, WHcPep4, WHcPep6) konnten 
aus E. coli Lysat gereinigt werden. Die Immunisierung von Mäusen zeigte, dass VLP eine 
bessere Immunantwort induzieren als eine Peptid-Immunisierung mit dem n-terminalen PreS1-
Fragment (aa 1-81). Bereits nach der ersten Impfung haben alle Mäuse, die mit VLP geimpft 
wurden, eine humorale Immunantwort gegen das PreS1-Protein entwickelt. Mäuse, die mit dem 
PreS1-Peptid (aa 1-81) geimpft wurden, zeigten zu diesem Zeitpunkt keine PreS1-spezifische 
Immunantwort. Die in dieser Studie hergestellten WHV Partikel können auf ihre Sicherheit und 
die Induktion protektiver Immunität untersucht werden, um in Zukunft HBV Partikel in 
klinischen Studien anzuwenden. 
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8. Appendix 
 
8.1. Plasmid maps 
 
Maps of vectors used during the experiments: 
 
 
 
 
Figure 23: Schematic map of PQE60. 
PQE60 plasmid was used for bacterial expression of the 149aa truncated wildtype WHcAg 
and for expression of WHcPep1-WHcPep6. The plasmid consists of: a c-terminally 6xHis 
tagged insert; restriction enzymes; T5 promoter and lac operator element; lambda 
transcription termination region; rrnB transcription termination region; ColE1-type origin of 
replication; ampicillin resistance gene (beta-lactamase cds). 
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Figure 24: Schematic map of pDEST24.  
pDEST24 plasmid was used for bacterial expression of the PreS1-GST protein. The plasmid 
belongs to Invitrogen Gateway technology plasmids. The plasmid consists of: a c-terminal 
GST insert; restriction enzymes; T7 promoter; T7 transcription termination region; pBR322 
origin of replication; ampicillin resistance gene. 
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Figure 25: Schematic map of pENTR/SD/D-TOPO.  
pENTR/SD/D-TOPO plasmid was used for cloning of preS1 gene into pDEST24 plasmid. 
The plasmid consists of: TOPO binding site; T7 promoter; rrnB T1 and rrnB T2 transcription 
termination region; pUC origin of replication; kanamycin resistance gene. 
 
 
 
8.2. Protein- and DNA- sequences  
 
Protein- and DNA-sequences used and generated during the experiments: 
 
 
 
 
Figure 26: WHcAg DNA and protein-sequence.  
For expression PQE60 plasmid was used.   
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Figure 27: WHcAg DNA and protein-sequence including Bsp119 restriction site.  
The PQE60 plasmid including this sequence was used for cloning of PreS1 peptides Pep1-
Pep6 into the MIR of WHcAg. Restriction site Bsp119 (BstBI) is highlighted in green.    
 
 
Figure 28: WHcPep1 DNA and protein-sequence.  
The PQE60 plasmid including this sequence was used for protein expression. The PreS1 
peptide Pep1 is highlighted in red. 
 
 
Figure 29: WHcPep2 DNA and protein-sequence.  
The PQE60 plasmid including this sequence was used for protein expression. The PreS1 
peptide Pep2 is highlighted in red.   
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Figure 30: WHcPep3 DNA and protein-sequence.  
The PQE60 plasmid including this sequence was used for protein expression. The PreS1 
peptide Pep3 is highlighted in red. 
 
 
Figure 31: WHcPep4 DNA and protein-sequence.  
The PQE60 plasmid including this sequence was used for protein expression. The PreS1 
peptide Pep4 is highlighted in red. 
 
 
 
Figure 32: WHcPep5 DNA and protein-sequence.  
The PQE60 plasmid including this sequence was used for protein expression. The PreS1 
peptide Pep5 is highlighted in red. 
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Figure 33: WHcPep6 DNA and protein-sequence.  
The PQE60 plasmid including this sequence was used for protein expression. The PreS1 
peptide Pep6 is highlighted in red. 
 
Figure 34: PreS1-GST DNA and protein-sequence.  
The Gateway pDEST24 plasmid including this sequence was used for protein expression. The 
PreS1 fragment is highlighted in green. 
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